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Major Depression is a serious mental illness which if left untreated can lead to severe mental and 
physical debilitation.  Major depression often occurs concurrently with many, serious, medical 
co-morbidities, e.g., diabetes mellitus.  Primary care physicians now have to treat more 
medically complex patients due to the increasing incidence of diabetes mellitus and the increase 
of screening for major depression in the primary clinic settings.  There are little data available 
about the impact of diabetes mellitus on depression treatment and this report will provide some 
of this data to the treating clinician.   
 The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) was the largest 
study of major depression in the U.S. to date, with an enrollment of 4041.  STAR*D offered a 
unique opportunity to examine the impact of diabetes on depression and antidepressant 
treatment.  This report focused on the presenting characteristics and treatment outcomes of 
diabetics from the first STAR*D treatment level. 
 At study entry, diabetics differed on key socio-demographic variables, e.g., race/ethnicity 
and reported lower physical functioning at baseline across measures of quality of life and 
depression severity.  Diabetics had poorer outcomes, although after adjustment for potential 
confounders, there was no statistically significant difference in these outcomes.  Diabetics 
received similar treatment regimens as non-diabetic participants and reported fewer side effects 
at the conclusion of the first treatment level with citalopram.  Diabetics also reported a lesser 
 iv
 overall impact of side effects than non-diabetics, although these results were limited by a lack of 
available baseline side effect data for comparison. 
 These findings are of some importance to clinicians.  The lack of an independent 
association of diabetes with major depression treatment response after adjustment for 
confounding factors implies that clinicians can treat diabetic patients similarly to those without 
diabetes mellitus for major depression.  This is of some public health significance as untreated or 
poorly treated major depression adversely impacts diabetes disease management, which in turn 
can lead to the development of life-threatening diabetes complications.  The importance of 
developing MDD treatment modalities that result in sustained remission for individuals with 
major depression and diabetes mellitus cannot be over-stated. 
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 1.0  INTRODUCTION 
Major depressive disorder (MDD) or depression is a highly prevalent mental disorder affecting 
approximately 9.5% of the US population aged 18 and older annually.1  If left untreated, 
depression can cause severe debilitation and physical impairment.  While it is acknowledged that 
the presence of a co-morbid disease can complicate or impair depression treatment, the impact of 
the presence of a serious co-morbid disease (e.g. Diabetes Mellitus) on the treatment of major 
depression is poorly understood.   
Diabetes Mellitus (DM) is approaching epidemic proportions within the United States 
and is of significant public health importance.  The National Institute of Diabetes and Digestive 
and Kidney Diseases (NIDDK) estimates that 20.8 million (7%) individuals have diabetes in the 
US and not all of them have been diagnosed.2 
 Screening for MDD has increased in primary care practices in response to the growing 
recognition of the debilitating effects of untreated MDD.  Primary care practitioners now have to 
manage patients with complex medical comorbidities and concurrent MDD.  There is little in the 
medical literature on the effects of medical comorbidities, e.g., DM on the response to MDD 
treatment.  Understanding the effect of Diabetes Mellitus on patients undergoing treatment for 
depression can provide valuable information to clinicians and lead to adjustments in current 
treatment modalities. 
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 1.1 REVIEW OF THE LITERATURE 
1.1.1 Overview of Depression  
Major Depressive Disorder (MDD), is fairly common within the general US population.  If left 
untreated, depression can cause physical and mental impairment and is associated with medical 
illnesses3, 4 and mortality.5  Symptoms of depression include: sad mood, change in appetite or 
weight, loss of interest or pleasure in activities that were once enjoyed, difficulty sleeping or 
oversleeping, physical slowing or agitation, energy loss, feelings of worthlessness or 
inappropriate guilt, difficulty thinking or concentrating, and recurrent thoughts of death or 
suicide.  The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)6 indicates 
that a diagnosis of MDD is made if an individual has 5 or more of these symptoms and 
impairment in usual functioning nearly every day during the same two-week period.6  Major 
depression often begins between ages 15 to 30, but also can appear in children.1 
  
1.1.2 Community Surveys 
There have been four population surveys of MDD and psychiatric disorders within the US over 
the past 20 years.  The first was the Epidemiological Catchment Area Study (ECA) which was 
conducted in the 1980’s.7  This study assessed the prevalence and incidence of mental disorders 
and the mental health services utilization in 5 urban areas.  The ECA utilized the Diagnostic 
Interview Schedule8 to estimate the prevalence of mental disorders in the general population.  
Over 18,000 non-institutionalized individuals living in 5 urban areas, New Haven, Baltimore, 
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 St.Louis, Durham and Los Angeles were surveyed.  DSM-III criteria were used to diagnose 
mental disorders.9  Estimates of lifetime MDD prevalence ranged from 3% to 5.9% and 12 
month prevalence ranged from 1.9% to 3.4% in the 5 ECA sites.7   
The National Comorbidity Survey Study (NCS) was mandated by the US Congress and 
conducted between 1990 and 1992.  It was the first nationally representative survey of the 
lifetime and current prevalence rates of psychiatric disorders among persons aged 15-54 in 5877 
US household residences.4,10  This study did not measure mental health services utilization, but 
instead examined the presence or absence of psychiatric disorders.  A modified version of the 
structured psychiatric interview, the World Health Organization’s Composite International 
Diagnostic Interview (CIDI)11 was utilized in the NCS.  The DSM-III-revised diagnostic criteria 
(DSM-III-R)12 were used in the diagnosis of MDD.  MDD and alcohol dependence were the 
most commonly diagnosed mental disorders with more than 17% of the respondents reporting at 
least one occurrence of MDD in their lifetime and over 10% reported an episode in the previous 
12 months4.  A high comorbidity with other DSM disorders was also observed.   
Several factors prompted a replication of the NCS, the NCS-R.3  These were: 1) the 
introduction of the new DSM-IV criteria13, 2) the growing public awareness of the health burden 
of depression and the changes in depression treatment regimens14 and 3) concerns that the 
estimates in the ECA study and the NCS were too high.  The NCS-R3 was conducted in 2001 
through 2003 in order to update the prevalence, correlates and course of minor and major 
depression using the DSM-IV criteria.13  This was a nationally representative survey of US 
adults aged 18 and older in households or group quarters and was conducted from 2001 through 
April 2003.15  This study was unusual in that data were collected in face-to-face interviews at the 
home of the respondents, as opposed to in a clinical setting.  DSM-IV criteria13 were used for the 
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 diagnosis of MDD and other psychiatric disorders.  These criteria differed from the earlier DSM 
criteria in that there was more emphasis on the clinical significance requirements for MDD 
diagnoses.3   
The diagnostic instrument was an expanded version of the World Health Organization’s 
Composite International Diagnostic Interview (CIDI).11  Lifetime and 12 month prevalence 
estimates for MDD were 16.6%16 and 6.7%17 respectively.  The prevalence estimates of MDD 
were found to be intermediate to the estimates determined from the ECA and the NCS.  Results 
from the NCS-R were comparable to that observed in Western Europe, where lifetime prevalence 
of MDD has been shown to be between 13.3% and 17.1%.3,18   
1.1.3 Risk Factors of Depression  
There are several major risk factors that are associated with depression.  These are: 1) previous 
history of depression, 2) family history of depression, 3) female gender, 4) general medical 
conditions (e.g., Diabetes Mellitus or hyperthyroidism), 5) substance abuse, e.g., alcoholism, 6) 
cognitive-behavioral and personality factors and 8) psychosocial factors and adverse or 
significant life events, e.g., stress, death.1   
The three most predictive risk factors for depression are previous history of depression, 
family history of depression and female gender.  According to the American Psychological 
Association at least 60% of individuals with a single episode of MDD are at an increased risk for 
subsequent episodes of depression especially if the first is untreated or under-treated.19,20  The 
risk of major depression increases substantially for both men and women if a first degree relative 
also has a history of depression.  It has been reported that children of depressed parents have 
between a two-fold and four-fold increased risk of major depression compared to children of 
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 non-depressed parents.21,22  There is also evidence for an earlier age of onset and increased 
severity of depression and recurrence in individuals with depressed parents.22   
Women are twice as likely as men to suffer from depression during their lifetime.23  In 
any given year, approximately 6.7 million adult females (6.5%) in the US are affected by 
depression compared to 3.2 million adult men (3.3%).23  It is unknown whether the higher rate of 
depression observed in women is due to the genetic, biological or psychosocial factors or a 
complex interaction of all these factors.  It should also be noted that men are less likely to report 
or seek help for depression and are more likely to mask it by alcohol and substance abuse or long 
work hours.24   
 
1.1.4 Treatment of Depression 
Depression treatment can be divided into three distinct phases: acute (12 weeks), continuation (4-
9 weeks) and maintenance (1 year or more).25,26  The goal of the acute phase is the remission of 
depressive symptoms with a minimization of side effects.26  The continuation and maintenance 
phases share the common goal of sustained remission through the prevention of relapse and 
recurrence, the reduction in suicidality and improving functioning and quality of life.  Patient 
complicance with the treatment regimen is crucial to maintaining sustained remission26,27 and 
patient compliance can be adversely affected by the occurrence of side effects in any of the 
treatment phases.28 
The development of antidepressant treatments goes back to the 1950’s and is based on the 
monoamine hypothesis.  The monoamine hypothesis postulates that the effects of depression are 
as a result of imbalances in the transmission of key neurohormones—serotonin, norepinephrine 
  5
 and dopamine.29  The development of the monoamine oxidase inhibitors (MAOIs) and the 
tricyclic antidepressants (TCAs) resulted from animal studies which showed that MAOIs acted 
by preventing the metabolism of monamines and TCAs blocked their reuptake at the cellular 
level.  Schechter et al, suggested that clinical data in the 1960’s showed that depletions in 
monoamines adversely impacted mood.29   
TCAs and MAOIs were effective antidepressants, but TCAs in particular were sometimes 
accompanied by fatal side effects, e.g., cardiac arrests.30  In the 1980’s the seretonin selective 
reuptake inhibitors (SSRIs) were introduced.  Examples of these were fluoxetine, paroxetine and 
sertraline.  These proved to be highly effective and were characterized by their ability to 
selectively increase serotonin levels at the cellular level by preventing the re-uptake of 
serotonin.29  They were characterized by a higher therapeutic index31 and the lack of receptor 
antagonism and potentially fatal side effects, e.g. cardiac arrest.30  
The most recent class of antidepressants is the serotonin/norepinephrine reuptake 
inhibitors (SNRIs) which block both the reuptake of serotonin and norepinepherine at the cellular 
level.  These third generation antidepressants have been shown to be more efficacious than the 
traditional SSRIs.32  One example is bupropion which has been shown to be an effective 
antidepressant and has less side side effects, e.g., weight gain and sexual dysfunction.33   
Despite the proven efficacy of the newer antidepressants, patient adherence to treatment 
regimens remains low.  Lin et al.,28 reported that up to 70% of patients taking antidepressants 
were non-compliant due to missed doses or premature discontinuation.  Side effects were 
reported to be the most common reason for discontinuation.34  The most commonly reported side 
effects to SSRIs are; 1) sexual dysfunction, e.g., decreased libido, 2) gastrointestinal effects, e.g., 
constipation and nausea, 3) weight gain and 4) central nervous system side effects, e.g., anxiety 
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 and sleep disturbances.34  Clinicians have to educate and reassure their patients about side effects 
to SSRIs, which while benign, can contribute to patient non-compliance through premature 
discontinuation of antidepressant treatment.   
 
1.1.5 Depression and Medical Illnesses 
Depression can lead to significant suffering, high morbidity and mortality and psychosocial 
impairment.35  It has been demonstrated that within the US, most individuals do not receive 
adequate treatment.4  This is due to a variety of factors that range from the lack of systematic 
ascertainment by primary care providers to the fear of social stigma that is attendant upon a 
diagnosis of mental illness within some communities.35  There is a significant burden of 
suffering, poor physical functioning, increased morbidity and impaired work productivity that is 
associated with MDD.   
Depression has been associated with many serious medical illnesses, e.g., myocardial 
infarctions,36,37 advanced cardiac disease,38 diabetes39 and poor glycemic control.40  The presence 
of a comorbid medical illness has been associated with a higher prevalence of MDD41 and 
comorbid medical illness is a major risk factor for MDD.  For example, Lustman et al., in 2000,42 
reported that patients with diabetes were 2-4 times more likely to have MDD.  This is of concern 
as the incidence of diabetes mellitus is rising in the US and implies that increased numbers of 
individuals will be at risk for MDD.   
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 1.1.6 Diabetes Mellitus-Definition and Description 
The American Diabetes Association has defined Diabetes Mellitus (DM) as, “…a group of 
metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, 
insulin action or both”.43  DM is a metabolic disorder of multiple etiologies that results in 
chronic hyperglycemia which can disrupt carbohydrate, protein and fat metabolism.  It is 
possible for deficiencies in insulin secretion to coexist with insulin resistance in the same 
individual.43  Hyperglycermia has a profound disruptive effect on all of the organ systems and its 
symptoms include; polyuria, polydipsia, weight loss and blurred vision.  Untreated 
hyperglycemia can result in ketoacidosis and the nonketotic hyperosmolar syndrome, which are 
life-threatening.43, 44  The cause of DM is unknown although genetic and environmental factors 
have been postulated as possible causal agents.   
There is a high degree of morbidity and mortality associated with DM, i.e., through the 
development of diabetes-related complications.  Many patients are asymptomatic or exhibit very 
subtle symptoms and frequently go undiagnosed for years.  When a diagnosis of DM is made, 
many patients already have fully-developed, diabetes-related complications.  Diabetes-related 
complications fall into two categories, microvascular and marcrovascular disease, both of these 
are associated with elevated mortality and morbidity in minority diabetics.  Microvascular 
disease includes retinopathy, end-stage renal disease and lower limb amputations.  The three 
main types of macrovascular disease are coronary disease, cerebrovascular disease, and 
peripheral vascular disease.45 
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 1.1.7 Classification of Diabetes Mellitus 
The American Diabetes Association (ADA) has classified 11 different types of DM based upon 
the etiology of the disease.43  DM can also result from a myriad of rare genetic disorders and 
immune syndromes, however, the majority of DM cases fall into two categories: Type 1 or Type 
2.43, 45   
 
1.1.8 Type 1 Diabetes Mellitus 
Type 1 Diabetes accounts for approximately 10% of Diabetes Mellitus cases in the US.45  Type 1 
DM was formerly known as “juvenile-onset diabetes mellitus” or “insulin-dependent diabetes 
mellitus”.  Two distinct types of Type 1 DM have been identified.  They are the non-immune or 
idiopathic form and the immune-mediated diabetes (common form).43  Idiopathic or non-immune 
Type 1 DM is the destruction of pancreatic beta cells in the absence of the autoantibodies.  
Immune-mediated DM is mediated by a combination of genetic and environmental factors that 
trigger specific autoimmune mechanisms associated with the destruction of beta cells in the Islets 
of Langerhans in the pancreas.  This results in the absence of pancreatic insulin secretion but 
normal cellular sensitivity to insulin.   
The pathogenesis of Type 1 DM is characterized by the presence of autoantibodies to 
glutamic acid decarboxylase (GAD), islet cells and precursors of insulin, e.g.ICA512, or insulin 
itself.45  A series of studies of non-diabetic patients showed the presence of elevated levels of 
autoantibodies to Islet of Langerhan cells and insulin years before there was evidence of 
hyperglycemia.44  Immunoflorescence microscopy has shown the presence of autoantibodies to 
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 islet cells in the serum of 70-80% of patients with newly diagnosed IDDM.44  A gradient has 
been observed when comparing the islet cell autoantibody titer of normal subjects, first-degree 
relatives and newly diagnosed patients with Type 1 DM.  Normal subjects and first degree 
relatives had respective autoantibody titers of <1% and 3-4% respectively.  Autoantibodies to 
GAD are found in the majority of individuals with fasting hyperglycemia.43  A higher risk of 
Type 1 DM appears to be associated with a younger age as well as a higher titer of 
autoantibodies.  This suggests that islet cell destruction occurs at a faster rate in younger patients 
than in adults leading to a faster progression towards the clinical manifestations of Type 1 DM.44  
Infants and children experience a rapid rate of beta cell destruction compared to adults.  In 
younger children, ketoacidosis is the first clinical manifestation of the disease.  Some younger 
children often present with fasting hyperglycemia that advances to severe hyperglycemia and 
ketoacidosis under the influence of stress or infection.  In contrast, adults can continue to 
produce residual amounts of insulin to delay ketoacidosis for many years.43, 44  
Autoimmune dysfunction, genetic predisposition and viral and environmental factors 
have been postulated as potential causal agents in the development of Type 1 DM.43,44  There is 
an extensive body of scientific literature that characterizes the role of genetics in the occurrence 
of this disease.  The major genetic susceptibility locus IDDM1 is located in the Human 
Leukocyte Antigen class II or HLA-DQA and B region on the short arm of chromosome 6.46  
Type 1 DM is also influenced by the DRB genes at this locus.  Research has shown that HLA-
DR/DQ alleles can confer either genetic protection or susceptibility.47  Approximately 50% of 
the genetic susceptibility to Type 1 DM has been shown to be localized in the HLA class II 
region.46   
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 A number of familial studies have shown that there is a strong genetic component to this 
disease.  Studies of monozygotic twins have shown that there is higher concordance rate for 
Type 1 DM (35-50%) when compared to the 5-10% observed in dizygotic twins.48  Further 
familial studies in European families have shown that the siblings of individuals with Type 1 
DM have a risk of 6%.49  Also there is a risk of 3% associated with having a diabetic mother.  
The risk doubles to 6% for children with a diabetic father.50  The role of environmental factors in 
Type 1 DM is suggested by the high rates of discordance observed in monozygotic twins.45  
Seasonal variations in disease onset and the rising incidences of Type 1 DM in previously stable 
populations further suggest that environmental factors may play an important role in the 
development of this disease.  These factors include pre-natal exposure to viruses, chemical 
toxins, and neonatal nutrition.45  
 
1.1.9 Epidemiology of Type 1 Diabetes Mellitus 
As has been previously mentioned, Type 1 DM accounts for less than 10% of the cases 
diagnosed annually in the US, but Type 1 DM remains the most common, chronic, childhood 
illnesses.43,45  Type 1 DM has been observed more frequently in individuals of Northern 
European descent than in those of African, Asian or Native American descent in the US.  World-
wide incidence ranges from 1to 2 per 100,000 per year in Japan to 35 to 40 per 100,000/yr in 
Finland51, giving rise to the observed ‘north-south gradient in incidence’.45   
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 1.1.10 Type 2 Diabetes Mellitus 
Type 2 DM is characterized by a decreasing sensitivity to insulin.  It is also formerly known as 
“non-insulin dependent diabetes mellitus”.  The etiology of Type 2 DM may range from 
predominantly insulin resistance with relative insulin deficiency to a predominantly secretory 
defect with insulin resistance. Type 2 DM is the most common form of diabetes.43, 45   
The concept of insulin resistance (IR) underlies all of the definitions of DM.  IR refers to 
impaired tissue sensitivity to insulin which results from decreased densities of insulin receptors 
on cell surfaces to a reduced intracellular response to insulin.  An increase in insulin secretion or 
hyperinsulinemia results from an attempt by the body to overcome IR.  Hyperglycemia then 
results as the pancreas is overwhelmed and can no longer produce excessive insulin.  IR, which 
is estimated to be prevalent in 10-25% of the general population, is one of the key stages in the 
development of Type 2 DM.  Reaven et al., (1988) defined a cluster of symptoms that occur in 
conjunction with IR or the Metabolic Syndrome.52  The metabolic syndrome describes the 
occurrence of elevated LDL cholesterol and triglycerides, obesity and hypertension with IR.  It 
has been estimated that ~25% of the general population meets the criteria for Metabolic 
Syndrome. 
 
1.1.11 Epidemiology of Type 2 Diabetes Mellitus 
Type 2 DM is on the rise in the US, particularly in the minority communities.40,53,54  The NIDDK 
estimates that 20.8 million people in the US (7%) have diabetes, of these, 6.2 million have not 
been diagnosed and 14.6 million have been diagnosed with Type 2.2  Recent estimates suggest 
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 that approximately 54 million individuals are pre-diabetic.2  Pre-diabetes is defined as the 
condition where an individual’s blood glucose levels are higher than normal but not high enough 
for a diagnosis of Type 2 DM.  Pre-diabetes is considered to be a strong risk factor in the 
development of DM.43   
 The American Diabetic Association (ADA) and the NIDDK have identified a number of 
risk factors for DM.  They include: 1) family history of diabetes, 2) >45 years of age, 3) Low 
HDL cholesterol, 4) previous impairment of fasting glucose, 5) females with a history of 
gestational diabetes, 6) females who have delivered an infant >9lbs, 7) obesity, 8) hypertension 
and 9) triglycerides >250mg/dL.43    
The contribution of socio-economic status to Type 2 DM is of some importance.  Medical 
illness has been inversely associated with socioeconomic status and Type 2 DM is no exception.  
Studies within the US55 and England56 have shown an inverse relationship between 
socioeceonomic status and diabetes.   
 
1.1.12 Other Specific Forms of Diabetes Mellitus 
Several types of DM have been identified43 and are associated with the following: 1) genetic 
defects of beta cell function, e.g., inability to convert precursors of insulin to insulin, 2) genetic 
defects in insulin action, 3) pancreatic diseases causing impaired insulin secretion, e.g., 
pancreatitis, 4) drug or chemical induced beta-cell dysfunction, 5) Endocrinopathies, e.g., 
Cushings syndrome, 6) Infections, e.g., congenital rubella and 7) gestational diabetes.  These are 
not commonly observed.   
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 1.1.13 Diagnostic Criteria for Diabetes Mellitus 
The diagnosis of DM is based on elevated levels of blood glucose or hyperglycemia.  The ADA 
has recommended the following criteria for the diagnosis of DM43:  
1) Symptoms of DM (polyuria, polysipsia and unexplained weight loss) as well as causal 
plasma glucose concentration ≥200mg/dl at any time of day irrespective of time since last 
meal.  (Causal is defined as any time of day without regard to time since last meal) or 
2) Fasting plasma glucose levels ≥126mg/dl where fasting is defined as no caloric intake for 
at least 8 hours or 
3) Oral Glucose Tolerance Test (OGTT) results where at 2 hours post glucose load, plasma 
glucose levels are at ≥200mg/dl 
 
1.1.14 Diabetes Mellitus and Mental Illness 
The co-occurrence of Diabetes Mellitus and psychiatric illness is not a new phenomenon.  Type 
2 DM has been found be fairly prevalent within the schizophrenic and bipolar disorder patient 
population, more so than the general population.57  In 1989, Mukherjee et al reported an overall 
15.8% prevalence rate of DM among schizophrenic patients.58  This was also shown in the US 
Surgeon General’s Report on Mental Health, when the self-reported rate of lifetime DM among 
schizophrenic patients was reported as 14.9%.24  In a more recent publication, Regenold et al.,59 
in 2002, reported that the rates of Type 2 DM among inpatients were 13% for schizophrenic 
patients, 26% for bipolar patients and 50% for schizoaffective disorder.59   
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 Several factors have been postulated to contribute to the higher rates of DM among 
psychiatric patients.  They are lifestyle, smoking, stress, genetics and medication effect.60  
Particularly with schizophrenia, many patients lead unhealthy lifestyles which can lead to the 
development of DM risk factors, such as obesity and high triglyceride levels.  Genetics can also 
have an impact on the development of DM with schizophrenic patients.  The rate of diabetes in 
family members of schizophrenics is 18%-30%.58  This is considerably higher than what has 
been observed in the general population (7%).   
There is conflicting evidence about an association between antipsychotic medication and 
DM in schizophrenics.  Within the medical literature, most of the work had been done on 
patients who had been exposed to antipsychotic treatment.  In a groundbreaking study of first 
episode, drug-naïve patients, it was observed that schizophrenic patients had statistically 
significant higher rates of impaired fasting glucose levels (pre-diabetes) and insulin resistance 
when compared to controls,(p<0.05).61   
 
1.1.15 Comorbidity of Depression and Diabetes 
It has been demonstrated in the medical literature that the prevalence of depression is increased 
among the diabetic population when compared to the general population.39, 62  It is also fairly 
well established in the medical literature that psychological distress and other diagnosable 
psychiatric disorders, e.g. major depressive disorder (MDD), eating and anxiety disorders 62, 63  
interact negatively with existing chronic conditions.  Gavard et al in 1993, 39 conducted a meta-
analysis of 9 controlled and 11 uncontrolled studies of diabetic patients with Type 1 and Type 2 
DM.  Gavard and Lustman established that the rate of depression was elevated among diabetic 
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 patients relative to the general population.39  They found that prevalence rates of depression were 
found to range from 22-60% in diabetic patient samples compared to 5-25% in the general 
population.  Diabetes appeared to double the likelihood of comorbid depression, which is present 
in approximately 30% of diabetic patients.64   
Anderson et al., (2001) estimated the prevalence of comorbid MDD in DM in a meta-
analysis of 42 studies across 18 controlled and 11 uncontrolled studies.40  It was determined that 
the diagnosis of DM doubled the odds of MDD and this was consistent across all studies.  
Prevalence estimates ranged from 26.1% vs. 9%, p<0.0001 (in self report-based estimates and 
interview-based estimates) to 34.9% vs. 14.2%, p<0.0001 (in uncontrolled studies).  However, 
the prevalence estimates of MDD were influenced by study design, sex distribution, origin of 
participants, sample size, type of depression and depression assessment methods.  MDD was 
found to be associated with DM, but the underlying mechanism of this association was unknown.   
Many of the factors that are linked to depression are not restricted to patients with 
diabetes.  Several studies indicate that when compared to normal controls, depression appeared 
to have a negative impact in patients with other chronic diseases63 such as cardiovascular 
disease65, HIV66 and asthma67 compared with normal control subjects.  Depression has also been 
shown to be a predictor of the onset of disability68 and of mortality.69  In fact it has been 
suggested by Fisher et al,70, 71 that the high prevalence of depression in is not unique to patients 
with diabetes and may be related to the general psychological distress of living in a complex 
world and having a major chronic disease. 
Talbot and Nouwen72 discussed the two existing hypotheses on the occurrence of 
depression in diabetics. The first stated that depression in diabetics resulted from biochemical 
changes that were directly related to the illness (DM) or its treatment.  Their review of the 
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 literature indicated that the initial onset of MDD was independent of the onset of Type 2 
diabetes, but remained unclear in Type 1 diabetes.  The second hypothesis stated that depression 
in diabetes resulted from the psychosocial demands or psychological factors related to the illness 
and its treatment, e.g., neurohormonal inbalances resulting from poor glycemic control or poor 
neurotransmitter function.  The authors suggest that there is an association between the course of 
MDD and DM in individuals with DM, but it is not independent.  This relationship is in fact 
influenced by interactions of genetics and the environment (both biologic and psychosocial).  
This is definitely plausible given the course of MDD in DM, i.e. recurrence and chronicity of 
MDD in DM.73   
Depression and other mental illness can complicate the treatment of many chronic 
illnesses.  Comorbid depression is associated with worse outcomes74 and is more treatment 
resistant 42.  Depression has a pervasive impact on the quality of life and a potential negative 
impact on diabetes management.42  This implies that the identification and treatment of 
depressive symptoms may have a favorable impact on diabetic outcomes, i.e., a decrease in the 
prevalence of diabetes-related complications.  
There has been a recent upsurge of interest in the impact of the psychological aspects of 
chronic disease in the medical literature.  This is due to the realization of the profound impact of 
chronic disease on day-to-day living and the high direct and indirect costs to the individual and 
to society.  These costs will continue to increase as the prevalence of DM increases and 
screening for depression increases in the primary care setting.   
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 1.1.16 The Treatment of Depression in Patients with Diabetes Mellitus 
The existing literature on the treatment of depression in people with diabetes is very limited.  
There is some evidence that psychotherapy and antidepressant therapy are just as effective in 
diabetics and they are in non-diabetics and that there are some additional beneficial effects on 
glycemic control.75  However, the effect of diabetes on the treatment of depression is unknown.   
To date there have been four controlled studies where the effect of antidepressant 
treatment/cognitive behavior therapy on depression severity and glycemic control in diabetics 
patients with MDD were examined76-79.  They are reviewed in Table 1.1 below.  In summary, 
these 4 controlled studies have shown consistently that diabetics with MDD respond favorable to 
antidepressant treatment.  However, there were inconsistent results on the improvements in 
glycemic control across all 4 studies.  These studies also lacked the statistical power to 
effectively measure the effects of depression treatment on depressive symptoms, depressive sub-
types, physical and mental functioning and diabetes symptom burden.   
All 4 of the controlled studies of MDD and DM have only been conducted in samples of 
patients with DM.  None of these studies have included comparisons to either a non-depressed, 
non-diabetic group or a depressed group without diabetes.  These comparisons will be useful to 
treating clinicians, especially in the primary care settings, as they adjust their medical treatment 
plans to accommodate an increasingly more medically complex patient population.  Only one 
study to date has compared the baseline characteristics of depressed patients with and without 
diabetes.  The findings of Petersen et al.,80 were limited by the small sample size (n=51 patients: 
34 non-diabetics, 17 diabetics) and as a result many of the statistical comparisons were 
underpowered.  Its strengths included the rigorous characterization of depressive symptoms and 
a clinical diagnosis of DM.  None of these existing studies has examined the association of a 
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diagnosis of DM on depression treatment response or the side effects experienced during MDD 
treatment.
 Table 1.1 Review of 4 controlled studies examining the effect of the treatment of major depressive disorder in participants with diabetes mellitus 
Author 
(year) 
Description of 
sample 
Setting Study Design Timeframe Depression  
Assessment  
Treatment Outcome  
Measures 
Results Limitations 
Lustman et 
al., (1997) 
68 diabetics (28 
with active 
MDD 
Community 
sample 
Randomized, 
placebo 
controlled, 
double masked 
trial 
8 weeks BDI Nortriptyline Depression 
severity rating 
 
Glycemic 
control using 
HbA1c
57% of treated 
patients  
remitted vs. 
35.7% of 
placebo-treated 
patients   
 
Non-depressed 
diabetics 
(controls) had 
no response to 
treatment   
 
Worsening 
glycemic control 
in  
treated patients 
observed 
 
 
 
 
 
Selection bias: 
Poor glycemic 
control required 
for eligibility 
 
 
Limited 
generalizability 
 
Short treatment 
duration 
 
No washout 
period 
Lustman et 
al., (2000) 
60 patients with 
MDD 
Community 
sample 
Randomized, 
placebo 
controlled, 
8 weeks BDI and 
HRSD 
Fluoxetine Depression 
severity rating 
 
Significantly 
more changes in 
depression 
Short treatment 
interval  
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 Author 
(year) 
Description of 
sample 
Setting Study Design Timeframe Depression  
Assessment  
Treatment Outcome  
Measures 
Results Limitations 
double masked 
trial 
Glycemic 
control using 
HbA1c
severity ratings 
on both BDI and 
HRSD  
 
Statistical 
trend towards 
a 
hypoglycemic 
effect 
Small sample 
size 
 
          
Lustman et 
al., (1998) 
51 diabetic 
patients with 
Type 2 DM and 
MDD 
Community 
sample 
Randomized, 
controlled trial 
10 weeks BDI Cognitive 
Behavior 
Therapy 
Depression 
severity rating 
 
Glycemic 
control using 
HbA1c
85% of patients 
in CBT group 
achieved 
remission of 
depression 
compared to 
27% of controls, 
p<0.001 
 
Trend towards 
improved 
glycemic control 
in treatment 
group 
 
 
 
Small sample 
size 
 
CBT group 
received 1 yr 
more education 
than control 
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Author 
(year) 
Description of 
sample 
Setting Study Design Timeframe Depression  
Assessment  
Treatment Outcome  
Measures 
Results Limitations 
Katon et al., 
(2004) 
329 patients 
with DM and 
comorbid MDD 
and/or dysthmia 
9 primary care 
clinics of a 
HMO 
Randomized 
clinical trial  
1 year Hopkin’s 
Symptom 
Checklist 90 
Usual care vs. 
enhanced 
education and 
support of 
antidepressant 
medication 
treatment  
Independent 
blinded 
assessments 
of depression, 
global 
improvement 
and 
satisfaction 
with care 
 
Intervention 
group showed a 
mean larger 
treatment 
response.  
 
Non significant 
changes in 
HbA1c
PHQ-9 used to 
screen for MDD, 
not DSM-IV 
Patients did not 
have to meet 
criteria for MDD 
 
Clinicians were not 
blinded to 
treatment arm 
          
Lustman et 
al., (1998) 
51 diabetic 
patients with 
Type 2 DM and 
MDD 
Community 
sample 
Randomized, 
controlled trial 
10 weeks BDI Cognitive 
Behavior 
Therapy 
Depression 
severity rating 
 
Glycemic 
control 
85% of patients 
in CBT group 
achieved 
remission of 
depression 
compared to 
27% of controls, 
p<0.001 
Trend towards 
improved 
glycemic control 
in treatment 
group. 
Small sample 
size 
 
CBT group 
received 1 yr 
more education 
than control 
 
PHQ-9: Patient Health Questionnaire, 9 item   BDI: Beck Depression Inventory   CBT: Cognitive Behavior Therapy              HbA1c: Glycated Haemoglobin test of glycemic control 
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 2.0  SPECIFIC AIMS 
The present study utilized data from the first level of treatment in the Sequenced Treatment 
Alternatives to Relieve Depression (STAR*D) study in order to address the association of DM 
with response to depression treatment.  The Sequenced Treatment Alternatives to Relieve 
Depression (STAR*D) was a multi-site, prospective, sequentially-randomized series of 
controlled trials which were designed to provide various combinations of pharmacotherapeutic 
and/or psychotherapeutic treatments to outpatients with depression at either primary/specialty 
clinic settings.  The specific aims and hypotheses of this project were as follows: 
 
I. Specific Aim: To determine if individuals with Diabetes Mellitus present with a more 
severe form of depression at entry into STAR*D and if this presentation varies by 
race/ethnicity and sex. 
 
Hypothesis: Individuals with Diabetes Mellitus will present with a more severe form of 
depression and this presentation will vary by race/ethnicity and sex. 
 
II. Specific Aim: To determine if diabetic participants have a poorer outcome at Level I exit 
than non-diabetics.   
 
Hypothesis: Diabetic individuals will have a poorer outcome at Level 1 exit when 
compared to non-diabetics.  
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 III. Specific Aim: To determine if individuals with Diabetes Mellitus experience more 
treatment side effects than non-diabetics. 
 
Hypothesis: Individuals with diabetes will experience either (i) a higher frequency of 
treatment side effects than non-diabetics or (ii) report higher intensity (ratings) of 
treatment side effects or (iii) report a higher degree of impairment in day to day 
functioning due to side effects. 
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 3.1 ABSTRACT 
Patients with major depressive disorder (MDD) have high rates of medical co-morbidities, and 
these can impair treatment of the MDD.  Yet little is known regarding associations between the 
presence of a serious co-morbidity and treatment of the MDD.  The purpose of this study was to 
examine the socio-demographic characteristics and clinical features of MDD outpatients and 
make comparisons between participants with and without diabetes mellitus (DM) to evaluate 
possible associations between these factors and the presence of co-morbid DM.   
We studied a cohort of 4041 participants with non-psychotic MDD (333 with DM, 3708 
without) who enrolled in the Sequenced Treatment Alternatives to Relieve Depression 
(STAR*D) study, a large-scale depression treatment protocol.  Socio-demographic and clinical 
data were gathered at study entry and comparisons made between participants with and without 
DM.   
Participants with DM were more likely to be male, older, black, Hispanic, unemployed 
and have less education.  We found no significant differences between groups regarding MDD 
course characteristics, depression severity, or work satisfaction.  Participants with DM reported 
significantly higher mental functioning and lower physical functioning, and were more likely to 
have atypical depression and less likely to have comorbid alcohol abuse/dependence.  Regarding 
specific depressive symptoms, participants with DM were significantly less likely to report mood 
reactivity and problems with concentration, but more likely to report increased appetite, 
psychomotor slowing and leaden paralysis.  There was no difference in depression severity 
reported by participants with and without DM.  DM was associated with poor physical 
functioning and specific patterns of depressive symptoms in participants with MDD.  
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3.2 INTRODUCTION 
Major depressive disorder (MDD) is a highly prevalent mental disorder [1] that affects 
approximately 7% of the general US population annually [2].  MDD is associated with a 
significant burden of suffering, poor physical functioning, increased morbidity and impaired 
work productivity [3].  Further, it has been demonstrated that within the US, most individuals 
with MDD do not receive adequate treatment [4].  
Patients with MDD report higher rates of co-existing medical morbidities than those 
without depression [5-8] (e.g., 17% - 27% of MDD patients report advanced cardiac disease [9]).  
The presence of co-morbid medical diseases can complicate or impair the treatment of MDD 
[10].  Conversely, depression and other mental illnesses can complicate the treatment of many 
chronic medical illnesses [11].  Comorbid depression is associated with worse outcomes, and 
both the depression and the chronic illness are more treatment resistant when they occur co-
morbidly [11].   
The co-occurrence of a psychiatric illness such as MDD and diabetes mellitus (DM) is 
relatively common, partly because psychiatric patients have a higher rate of DM than the general 
population.  Several factors have been postulated to contribute to this higher rate, including 
lifestyle (e.g., smoking, stress, etc.), genetics and medication effects [12].  In 1999, 
approximately one million individuals in the US had both DM and MDD at any given time [13].   
Depressed individuals with DM report higher utilization of medical care facilities and 
higher rates of hospitalization than depressed patients without DM.  Overall, total health care 
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 costs for depressed individuals with DM are 4.5 times higher than those for depressed 
individuals without DM [14].  These costs will continue to escalate as both the prevalence of DM 
and the screening for depression in the primary care setting increase.  In addition, depression has 
a negative impact on a patient’s quality of life and can have a detrimental effect on diabetes 
management [15, 16].  This implies that the identification and successful treatment of depressive 
symptoms in patients with DM may improve diabetic outcomes.  Understanding the effect of a 
serious comorbidity on depressed patients can also provide valuable clinical information on 
adjustments in current treatment modalities and long term prognosis.   
The existing literature on the impact of DM on treatment of depression is limited.  A few 
studies have examined the impact of the treatment of depression in patients with DM in a 
controlled setting [17-20]; however, they all lacked a true comparator group (i.e., a non-diabetic, 
depressed control group).  At this time, there is only one study in the available medical literature 
which compared the characteristics of depressed diabetic patients to depressed patients without 
diabetes [21], however, the small sample size limited the generalizability of the results.   
The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study [22, 23] 
was the largest study of depression ever conducted in the US.  It provided a unique opportunity 
to cross-sectionally characterize the observed differences in socio-demographic characteristics 
and clinical features of depression in participants with and without DM at enrollment, 
independent of depression treatment. 
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3.3 METHODS 
Description of STAR*D 
STAR*D was a multi-site, prospective, sequentially-randomized series of controlled trials 
designed to define prospectively which of several pharmacotherapeutic and/or psychotherapeutic 
treatments were most effective for outpatients with nonpsychotic MDD who did not have a 
satisfactory clinical outcome to an initial and, if necessary, subsequent treatment(s).  The study 
was carried out in primary and specialty care clinic settings.  While the methodology of 
STAR*D has been described in greater detail elsewhere [22, 23], the key elements are described 
in detail below.   
 Participants were enrolled into the first level of STAR*D (Level 1), a 12-14 week course 
of treatment with clinic visits at weeks 0 (baseline), 2, 4, 6, 9, 12 and potentially 14.  Initially, all 
participants were treated with the standard serotonin re-uptake inhibitor, citalopram.  Depression 
severity and side effect burden were assessed at each clinic visit and these assessments 
determined if the participant had achieved a satisfactory clinical response.  Participants who 
experienced an adequate clinical response to Level 1 treatment entered a 12-month naturalistic 
follow-up phase.  Participants without a satisfactory clinical outcome to Level 1 were eligible to 
enter a series of successive randomized clinical trials that involved switching and 
combinations/augmentation strategies of antidepressants and psychotherapy for depressed 
patients.   
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STAR*D Organization 
The STAR*D infrastructure included the National Coordinating Center in Dallas (NCC), the 
Data Coordinating Center in Pittsburgh (DCC), and 14 Regional Centers (RCs) across the United 
States.  The staff at each RC oversaw implementation of the protocol at two to four Clinical Sites 
(CSs) that provided primary or psychiatric care to either the public or private sector.  CSs 
consisted of medical practices that did not normally participate in clinical research, and were 
identified based on the availability of a large number of potential patients with depression, 
adequate availability of clinicians and administrative support, and a representative number of 
minority patients with MDD.  Approximately 42% (18/41) of the CSs were primary care settings 
and almost all (13/14) of the RCs oversaw at least one primary care CS. 
 
STAR*D Recruitment  
STAR*D enrolled 4041 male and female outpatients, ages 18-75, with a DSM-IV diagnosis of 
non-psychotic MDD.  STAR*D enrolled only patients seeking treatment; recruitment through 
advertising was not permitted.  All risks, benefits and adverse events associated with each 
treatment were explained to study participants, who provided written informed consent prior to 
study participation.  The STAR*D protocol was developed in accordance with the principles of 
the Declaration of Helsinki, and was approved by the Institutional Review Boards at the NCC, 
the DCC and the respective RCs and CSs.  Data were collected using HIPAA guidelines.   
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 Inclusion/Exclusion Criteria 
STAR*D employed broad inclusion and minimal exclusion criteria to ensure a participant 
sample representative of patients who receive treatment for depression in everyday practice.  The 
inclusion and exclusion criteria for STAR*D are described in detail elsewhere [22, 24]. 
 
STAR*D Data Collection 
Trained Clinical Research Coordinators (CRCs) and clinicians administered assessment 
questionnaires to participants and collected self-report measures at each clinic visit.  Research 
outcomes (function, quality of life, side effect burden, and participant satisfaction) were 
collected at baseline and at each level exit via a telephone-based Interactive Voice Response 
(IVR) system and by the masked, independent Research Outcome Assessors (ROAs).   
Socio-demographic and clinical data were collected by the CRCs at baseline.  These 
included data on general medical conditions (GMCs), family history of mood disorders, suicide 
attempts and substance abuse.  Depression ratings were obtained utilizing the 17-item Hamilton 
Rating Scale for Depression (HRSD17) [25, 26], the 16-item Quick Inventory of Depressive 
Symptomatology– Clinician-rated (QIDS-C16) and the 16-item QIDS-SR16 (Self-Report) [27]. 
Medical comorbidities were assessed using the 14-item Cumulative Illness Rating Scale 
(CIRS) [28] to gauge the severity/morbidity of GMCs relevant to different organ systems.  The 
CIRS was administered at the baseline visit using a manual to guide scoring [29].  Each GMC 
category was rated on a five point scale (0-4).  The total CIRS score was obtained by a 
summation of the ratings from each category.  For the purposes of this report, the rating for the 
CIRS Endocrine category was excluded from the CIRS summary score as it was used in the 
definition of DM.   
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 The presence of psychiatric comorbidities was determined using the Psychiatric 
Diagnostic Screening Questionnaire (PDSQ) [30, 31], a self-administered instrument used to 
assess the presence or absence of 11 psychiatric disorders: Bulimia, Agoraphobia, Post-
Traumatic Stress Disorder, Generalized Anxiety Disorder, Obsessive Compulsive Disorder, 
Panic Disorder, Social Phobia, Alcohol Abuse/Dependence, Drug Abuse/Dependence, 
Hypochondriasis and Somatoform Disorder [30-32].   
Non-STAR*D medications used by participants throughout the study were recorded in 
the non-STAR*D Medication Log (ML), which included the following information: 1) name of 
the medication, 2) STAR*D medication code which corresponded to the type/general category of 
drug being used by the participant (using the STAR*D Medication Code List), 3) medication 
dosage, 4) indication (reason for use), and 5) start and stop dates of use for each medication.   
ROAs collected the HRSD17 (primary outcome measure), the 30-item Inventory of 
Depressive Symptomatology – Clinician-rated (IDS-C30) [33-35], and the 5-item Income and 
Public Assistance Questionnaire (IPAQ) via telephone interview within 72 hours of Level 1 
enrollment.  Three subtypes of depression, anxious, atypical and melancholic, were defined using 
the HRSD17 and IDS-C30.  Anxious depression was defined as an HRSD17 Anxiety/Somatization 
Factor score ≥7 [36].  The atypical [37] and melancholic [38] subtypes were defined based on the 
presence of specific symptom criteria from the IDS-C30.   
Information on participant satisfaction, physical and mental functioning, and work 
productivity were collected via the IVR System.  Participant satisfaction was assessed using the 
Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).  The Q-LES-Q was 
designed to measure satisfaction and enjoyment, as opposed to function per se, in various 
domains: physical health, mood, work, household duties, school/course work, leisure time 
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 activities, social relations, and general activities[39].  The 12-item Short Form Health Survey 
(SF-12) was used to collect data on mental and physical functioning [40].  It is a generic measure 
of health and has 2 subscales from which mental functioning and physical functioning can be 
assessed.  
 
Criteria for Classification of Diabetic Participants  
Participants were classified by diabetic status using the CIRS and the ML.  An individual was 
considered to have DM if one or both of the following criteria were met:  
 
1)  Diabetes had been reported on the CIRS 
2)  The STAR*D participant reported use of oral hypoglycemic medication and/or 
insulin at baseline (recorded on the ML). 
 
Agreement of Diabetes Classification 
Charts of 178 STAR*D participants from the University of Pittsburgh Medical Center’s (UPMC) 
Bellefield Clinic (a STAR*D CS) were reviewed to evaluate the accuracy of the participants’ 
self-report of diabetic status at entry (STAR*D criteria) with a diagnosis of DM by medical 
evaluation.  An Honest Broker abstracted and de-identified the required participant medical 
information in accordance with the University of Pittsburgh’s and UPMC’s policies and the 
HIPAA standards for de-identification.  Participants were identified as having DM if one or 
more of the following medical chart criteria were met [41, 42]: 
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 1. Laboratory tests: 
• Symptoms of diabetes plus plasma glucose concentration ≥200mg/dl 
• Glycosylated hemoglobin   
• Fasting blood glucose (≥126mg/dl) 
• Impaired glucose test (venous whole blood: ≥110 mg/dl fasting or ≥200 mg/dl 2 
hour post glucose load) 
2. The ICD 9 codes for DM [42] and its complications (e.g., cardiovascular disease 
retinopathy, renal disease, neuropathy, etc.)    
3. Physician notes indicating the presence of DM (Axis III and Axis IV notes)  
4. Oral hypoglycemic medications and/or insulin  
 
Data Analysis  
The kappa statistic was used to assess the agreement not due to chance of the self-report of DM 
status (from STAR*D criteria results) with the diagnosis by clinical evaluation [43].  An 
acceptable measure of agreement between the two sources of data ranged from 0.4 to 0.7 [44-
46]. 
Baseline STAR*D data were used for the purposes of this report.  Descriptive statistics, 
including measures of central tendency and dispersion, were calculated for all continuous 
variables.  Frequency distributions were determined for all categorical data.  The Chi-Square 
statistic and the exact Fisher’s Test were used to determine statistical differences in the discrete 
baseline characteristics between participants with and without DM.  The normality of the 
distributions of the continuous variables was tested using the Kolmogorov-Smirnov statistic.  
The Students t test was used to determine the statistical significance for comparisons of normally 
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 distributed continuous variables and the Wilcoxon was used for comparisons of non-parametric 
continuous variables.  
Logistic and linear regression models were used to assess the strength of associations 
between DM and dichotomous and continuous characteristics, respectively.  Associations 
between DM and continuous dependent outcomes were assessed using generalized linear models.  
The individual symptoms from the IDS-C30 were collapsed for analysis, such that a score of zero 
indicated the absence of a depressive symptom and a score >0 indicated the presence of a 
depressive symptom.  The association between the presence of a depressive symptom and DM 
was assessed using logistic regression models 
For each characteristic, two adjusted analyses were performed ―one without and another 
with the CIRS summary score.  This was done to address the multi-organ system impact of DM.  
Statistical significance for all tests was set at p<.05.  No adjustments were made for multiple 
comparisons, so results must be interpreted accordingly. 
 
3.4 RESULTS 
Data abstracted from the subset of 178 participant medical charts utilizing the chart abstraction 
criteria yielded 5 participants with DM (Appendix A).  In contrast, the STAR*D criteria 
identified 8 participants with DM.  All of the 5 participants identified by chart abstraction were 
also classified as having DM using the STAR*D research data.  The STAR*D criteria identified 
170 participants as not having DM.  These participants were also classified as not having DM 
among the 173 so identified using chart abstraction.  The measure of agreement between the 
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 STAR*D criteria data and the data from the chart abstraction was κ=0.76 (95% CI: 0.51-1.00), 
which indicated fair to good agreement between the chart abstraction and the STAR*D criteria 
data.  In the medical literature, for most purposes a value of kappa between 0.4 and 0.7 may be 
taken to represent fair to good agreement beyond chance [46].  
From the review of STAR*D data, 8.2% of the enrolled participants were identified as 
having DM (333/4041).  The data in Table 3.1 summarize the baseline socio-demographic and 
clinical course characteristics of STAR*D participants with and without DM.  Participants with 
DM were more likely to be male, older or to have completed fewer years of education.  
Participants with DM were also more likely to be African-American, Hispanic, or unemployed.   
 
Table 3.1 Differences in baseline socio-demographic characteristics in diabetic and non-diabetic 
STAR*D participants 
 
Characteristic Diabetic 
N=333 
Non-diabetic 
N=3708   
  n % n % p 
Gender       0.040 
Female 191 57 2341 63  
Male 142 43 1367 37  
Setting       <0.0001 
Primary Care 197 59 1378 37  
Specialty Care 136 41 2330 63  
Race       <0.0001 
White 220 66 2835 76  
Black 95 29 614 17  
Other* 18 5 259 7  
Hispanic       <0.0001 
No 266 80 3267 88  
Yes 66 20 441 12  
Marital status       <0.0001 
Married 162 10 1501 90  
Never married 56 5 1151 95  
Divorced 90 9 947 91  
Widowed 25 20 103 80  
        
Employment status        <0.0001 
Employed 125 37 2186 59  
Unemployed 166 50 1323 36  
Retired 42 13 193 5  
*Other = Multiracial, Native American. Alaskan/Pacific Islander, Asian American 
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 Table 3.1 (continued) 
 
 
Characteristic 
  
 
Diabetic 
N=333 
Non-diabetic  
N=3708 
 
  Mean (SD) Median 
(Min,Max) 
Mean (SD) Median 
(Min,Max) p 
Age 50.5 (13.1) 51 (18,73) 39.6 (13.1) 39.0 (18,75) <0.0001 
General medical 
comorbidities** 
Total score 
Total categories 
selected 
Severity 
 
 
6.6 (4.1) 
4.08 (2.2) 
 
1.6 (0.5) 
 
 
6 (0,30) 
4 (0,10) 
 
1.6 (0,4) 
 
 
3.6 (3.2) 
2.6 (2.1) 
 
1.1 (0.7) 
 
 
3 (0,4) 
2 (0,11) 
 
1 (0,4) 
 
 
<0.0001 
<0.0001 
 
<0.0001 
Years of education 12.3 (0,27) 12 (0,27) 13.6 (3.14) 13 (0,26) <0.0001 
Age at first MDE** 32.1 (16.7) 31.0 (4,73) 24.9 (14.0) 20 (2,74) <0.0001 
Number of 
MDEs** 
7.0 (13.0) 2 (1,99) 5.8 (11.2) 3 (1,99) 0.780 
Index Length 
(months)** 
31.9 (66.9) 11.21 (0,670.2) 24.1 (51.6) 7.6 (0,699.3) 0.001 
Years since first 
MDE** 
18.6 (15.3) 16 (1,63) 14.7 (12.9) 11(1,64) 0.0001 
Total Income** 
(monthly) 
1959  
(2428.9) 
1212 
(0,20800) 
2464 
(3240) 
1600 
(0,50000) 
0.001 
*General medical comorbidities: Summary scores calculated without endocrine category ratings 
** Wilcoxon Rank Sum used for significance testing 
MDE=Major Depressive Episode 
 
 
Participants with DM consistently endorsed a larger number of CIRS system categories 
and received a higher CIRS summary score.  We found significant differences between the 
clinical course characteristics reported by diabetic status.  Participants with DM showed a later 
age of first major depressive episode (MDE), a greater number of MDEs, a greater length of 
index case, and a greater number of years since first MDE (Table 3.1).   
The data in Table 3.2 summarize measures of depression severity, types of depression, 
quality of life and functioning for STAR*D participants with and without DM.  There were no 
differences noted in the mean baseline depression severity for the QIDS-SR16, IDS-C30 and the 
HRSD17.  In addition the distributions of the scores among those with and without DM were 
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remarkably similar (HRSD17 shown in Figure 3.1).  We found no significant differences in 
quality of life, enjoyment and satisfaction (measured using the Q-LES-Q) and work satisfaction 
(measured using the WSAS) between MDD participants with and without DM.  Analysis of    
SF-12 scores showed that participants with DM reported a higher degree of mental functioning, 
which was statistically significant but perhaps not clinically meaningful, and a lower degree of 
physical functioning.  Participants with DM were also more likely to have atypical depression 
than those without DM.  
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Figure 3.1 Distribution of HRSD17 (Hamilton Rating Scale for Depression, 17 item) scores by diabetes status 
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 Table 3.2 Association of diabetes mellitus with depression severity, depression type, quality of life and functioning in diabetic and non-
diabetic STAR*D participants 
 
Characteristic Diabetic Non-diabetic Diabetic Non-diabetic   
 N=333 N=3708 Adjusted *Least Adjusted* Least p p 
  Mean (SD) Mean (SD) Square Means Square Means Unadjusted Adjusted* 
QIDS-SR16 Total Score1 15. (4.6) 15.4 (4.3) 15.5 15.4 0.54 0.840 
HRSD17 Total Score2 20.6 (6.3) 19.9 (6.5) 19.6 19.9 0.07 0.330 
IDSC30 Total Score3 36.6 (11.9) 35.5 (11.5) 35.3 35.6 0.14 0.590 
SF-124 
MCS-125 
PCS-126
30.2 (9.7) 
40.2 (11.5) 
26.3 (8.5) 
50.1 (11.7) 
27.9 
46.1 
26.6 
49.6 
<.0001 
<.0001 
0.014 
<.0001 
WSAS7  23.9 (10.6) 23.5 (9.2) 2.33 23.5 0.5 0.740 
QLESQ8 39.8 (17.3) 41.9 (15.0) 41.6 41.8 0.018 0.830 
       
* Corrected for age, sex, race, Hispanic ethnicity and adjusted CIRS total score 
1Quick Inventory of Depressive Symptomatology, Self Report, 16 Item Total Score 
2Hamiliton Rating Scale for Depression, 17 Item, Total Score 
3Inventory of Depressive Symptomatology, 30 Item, Total Score 
4Short Form Health Survey, 12 item 
5Mental Functioning Total Score 
6Physical Functioning Total Score 
7Work Satisfaction and Activities Scale Summary Score 
8Quality of Life, Enjoyment and Satisfaction Scale Summary Score 
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Table 3.2 (continued) 
 
 Diabetic 
N=333 
Non-diabetic 
N=3708 
Unadjusted 
 
Adjusted* 
Depression Type n % n % OR p OR p 
Anxious Depression     1.53 0.0004 1.08 0.550 
Yes 141 45 1572 44     
No 171 55 1979 56     
Atypical Depression     1.43 0.014 1.49 0.010 
Yes 68 22 583 16     
No 243 78 2969 84     
Melancholic Depression     0.89 0.390 0.82 0.220 
Yes 56 18 709 20     
No 256 82 2844 80     
* Corrected for age, sex, race, Hispanic ethnicity and adjusted CIRS total score  OR=Odds Ratio 
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The data in Table 3.3 show the prevalence of individual depressive symptoms from the 
IDS-C30.  After adjusting for confounding factors, we found that participants with DM were less 
likely to report mood reactivity, problems with concentration and a decrease in involvement than 
participants without DM.  Diabetic participants were also more likely to report an increase in 
appetite and leaden paralysis.   
The associations of DM with psychiatric comorbidities (as measured by the PDSQ) are 
summarized in Table 3.4.  Participants with DM were significantly less likely to have comorbid 
alcohol abuse/dependence.  Hypochrondriasis was more prevalent among participants with DM, 
but this association did not remain statistically significant after adjustment for potentially 
confounding factors.
 Table 3.3 Symptoms of depression using the IDS-C30 items by diabetes status in STAR*D participants 
 Diabetic   Non-diabetic       
 N=333  N=3708       
 Present  Present   Unadjusted Adjusted* 
IDS-C30 Item Descriptor n % n % OR p OR p 
Onset Insomnia 201 67 2346 68 0.96 0.750 0.82 0.140 
Middle Insomnia 265 89 2762 80 1.91 0.0005 1.07 0.720 
Early Morning Insomnia 184 61 1797 52 1.47 0.002 0.96 0.730 
Hypersomnia 56 19 868 25 0.68 0.010 1.04 0.790 
Mood (sad) 288 96 3355 97 0.71 0.290 0.85 0.650 
Mood (anxious) 235 79 2816 81 0.82 0.180 0.9 0.50 
Panic 241 81 2822 82 0.92 0.580 0.8 0.160 
Mood (irritable) 116 39 1315 38 1.02 0.850 0.86 0.230 
Mood reactivity 196 66 2547 74 0.68 0.002 0.75 0.030 
Mood variation 57 19 780 23 0.81 0.160 0.88 0.410 
Quality of mood 224 75 2578 75 1 0.970 1.01 0.940 
Appetite increase 81 27 737 21 1.36 0.020 1.43 0.014 
Appetite decrease 126 42 1557 45 0.88 0.30 0.86 0.250 
Weight increase 76 25 787 23 1.15 0.310 1.11 0.460 
Weight decrease 95 32 1055 31 1.06 0.680 1.01 0.960 
Concentration 254 85 3125 91 0.58 0.002 0.56 0.002 
Outlook (Self) 223 75 2806 81 0.67 0.004 0.89 0.410 
Outlook (Future) 232 78 2646 77 1.04 0.780 1.07 0.640 
Suicidal Ideation 146 49 1657 48 1.03 0.820 0.99 0.990 
Involvement 243 81 2952 86 0.73 0.040 0.71 0.04 
Pleasure 213 71 2459 71 0.99 0.960 0.96 0.770 
Energy 272 91 3093 90 1.15 0.510 1.04 0.860 
Sexual Interest 196 66 2198 64 1.08 0.550 1.01 0.920 
Psychomotor slowing 215 72 2139 62 1.56 0.001 1.25 0.110 
Psychomotor agitation 174 58 2161 63 0.83 0.120 0.78 0.050 
Somatic complaints 239 80 2634 76 1.23 0.170 0.86 0.360 
Sympathetic arousal 226 76 2328 68 1.49 0.005 0.89 0.420 
Gastrointestinal 149 50 1434 42 1.39 0.006 0.97 0.790 
Interpersonal sensitivity 162 54 2119 62 0.74 0.013 0.95 0.700 
Leaden paralysis 173 59 1493 43 1.79 <0.0001 1.33 0.030 
*Corrected for age, sex, race, Hispanic ethnicity and adjusted CIRS total score      OR=Odds ratio
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Table 3.4 Prevalence of psychiatric comorbidities by diabetes status in STAR*D participants 
 
 Diabetic 
N=333 
Non-diabetic 
N=3708 
    
 Absent Present Absent Present Unadjusted Adjusted 
 n % n % n % n % OR p OR p 
OCD1 81 86 46 14 3154 86 508 14 1.01 .940 0.77 0.15 
Panic 84 87 44 13 3225 88 437 12 1.14 .430 0.87 0.43 
Social Phobia 46 75 81 25 2577 71 1079 30 0.79 0.07 0.95 0.70 
PTSD 66 82 59 118 3014 82 266 18 1.03 .85 0.79 0.15 
Agoraphobia 83 86 45 114 3263 89 391 11 1.33 .095 0.89 0.52 
Alcohol abuse 10 95 18 55 3209 88 454 12 0.41 .003 0.39 0.0002 
Drug abuse 12 95 16 55 3371 92 287 8 0.60 .054 0.78 0.360 
Somatoform 15 96 13 44 3575 98 82 2 1.80 .054 1.18 0.620 
Hypochondriasis 304 93 24 77 3512 96 146 4 1.90 .005 1.27 0.330 
Bulimia 90 92 38 88 3215 91 290 8 0.94 .720 1.18 0.400 
Anxiety 59 79 69 221 2892 79 766 21 1.01 .97 0.89 0.450 
*Corrected for age, sex, race, Hispanic ethnicity and adjusted CIRS total score  
1Obsessive Compulsive Disorder 
OR=Odds Ratio
 3.5 DISCUSSION 
Our finding of DM in 8.2% of participants with DM was slightly higher than the current estimate 
of 6.3% in the general population [47], which confirms a higher rate of DM among patients with 
MDD than in the general population.  Overall, the baseline socio-demographic characteristics of 
participants with DM mirrored what has been observed in other studies [48, 49].  STAR*D 
participants with DM were more likely to be African-American or Hispanic than Caucasian.  
This higher prevalence of DM observed in minority populations can, in part, be explained by 
socio-economic factors (i.e., reduced access to health care and/or utilization of poorly 
performing health care systems) [50].  An inverse relationship between socioeconomic status and 
DM has also been observed in contemporary industrialized countries [50-52].  STAR*D 
participants with DM were also more likely to have a greater number of medical comorbidities 
and experience more severe impairment from GMCs than those without DM.  These findings 
may provide at least a partial explanation for the higher health care costs and higher rates of 
hospitalization and medical care facility use reported by depressed individuals with DM [14].  
We found no difference in depression severity ratings or ratings of quality of life, 
enjoyment and satisfaction (Q-LES-Q) for STAR*D participants with and without DM.  This is 
in contrast to the findings of Petersen et al., [21] who reported more severe depression and lower 
rates of somatic well being and contentment in depressed patients with DM than in depressed 
patients without DM.  Also in contrast to our study, Petersen et al. did not find any statistically 
significant differences between depressed patients with and without DM regarding socio-
demographic characteristics, clinical features of depression and depression sub-types.  This 
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 previous study was the first to compare such characteristics between depressed patients with and 
without DM.  Though its design included a rigorous characterization of depressive symptoms 
and a clinical diagnosis of DM, many of its statistical comparisons were underpowered due to 
small sample size (N=51; 17 diabetics and 34 non-diabetics). 
STAR*D MDD participants with DM scored higher than those without DM in the SF-12 
mental functioning and physical functioning subscales, but only the higher physical functioning 
remained after adjustment.  This contrasts with previous studies that showed patients with MDD 
and DM consistently scoring lower on measures of mental health and physical functioning than 
patients with DM and no depression [53-55].  Goldney et al. [53] found significantly lower 
scores on the mental health and physical functioning components of the 36-item Short Form 
Health Survey (SF-36) for participants with DM vs. those without, and for participants with 
depression in DM vs. those without depression in DM, however, these comparisons were not 
adjusted for any socio-demographic or clinical characteristics (e.g., age and GMCs) [53].  It 
could be inferred that the higher mental functioning score could be attributed to the intensive 
disease management that is required by DM.  
Consistent with the diagnosis of DM, diabetics reported higher rates of appetite increase 
and psychomotor slowing.  Overall, diabetics endorsed more “physical” symptoms of depression 
than non-diabetics.  Fewer diabetics endorsed “cognitive” depressive symptomatology, e.g., loss 
of concentration. 
The strengths of STAR*D include the large sample size of 4041 participants, the 
recruitment of participants from both primary and psychiatric care settings, and a large 
proportion of minority participants (~25%).  This allows increased generalizability of the 
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 findings.  As the design of STAR*D Level 1 is cross-sectional, no causal inferences can be 
drawn from these study findings.   
This study has several limitations.  STAR*D was primarily a study of depression, not of 
DM or other GMCs.  Data on the absence/presence of GMCs was ascertained by participant self-
report on the CIRS and was not confirmed by medical diagnosis.  The CIRS is a very broad 
instrument that assesses the presence and morbidity of GMCs relevant to different organ systems 
(e.g., vascular, neurological, etc.)  An additional criterion was added for DM identification to 
address this limitation: DM was identified through participant self-report on the CIRS and/or the 
use of oral hypoglycemic medication or insulin.  To address the multi-organ system impact of 
DM, all multivariate analyses were performed twice, with and without the CIRS summary score.   
In addition, the lack of a clinical diagnosis of DM was addressed through independent 
review of a sub-sample of participant medical chart data.  As described in the Results section, we 
had a very good agreement between the chart abstraction and the STAR*D research criteria data.  
The reliability of data obtained from participant self-report and medical chart abstraction has 
been assessed previously in several studies [56, 57].  Overall, it has been found that participant-
completed questionnaires may be a very reliable source of information for epidemiological 
purposes with regard to a well-defined chronic disease such as DM [58]. 
In conclusion, analysis of the STAR*D data showed that key socio-demographic factors 
(e.g., sex, age, race, Hispanic ethnicity, etc.) and poor physical functioning of MDD patients with 
DM are associated with the DM.  Our findings also show that depressed diabetic patients were 
remarkably similar to non-diabetic depressed patients in key clinical features of MDD and 
depression severity.  However, diabetics appeared to experience more ‘physical’ symptoms of 
depression than non-diabetics.  This association persisted after adjustment for age and GMCs.  
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 This may suggest possible avenues for adjustments in current treatment modalities for MDD in 
depressed diabetic patients.  Previous research has shown that diabetic patients with MDD 
respond favorably to both pharmacotherapy and psychotherapy in depression treatment [17-19, 
59].  When treating patients with MDD and DM, clinicians may want to consider cognitive 
behavior therapy, which is targeted towards the more “physical” aspects of depressive 
symptomatology [21], as well as more aggressive pharmacotherapy.   
Future studies will focus on differences in depression treatment response and side effects 
due to depression treatment experienced by STAR*D participants with and without DM. 
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 4.1 ABSTRACT 
Individuals with Diabetes Mellitus (DM) are 2-4 times more likely to be diagnosed with Major 
Depressive Disorder (MDD).  However, few controlled studies have examined the impact of DM 
on the treatment of MDD.  Understanding the effect of DM on depressed patients could provide 
valuable clinical information toward adjusting current treatment modalities to produce more 
effective treatment for depressed patients with DM.  This study was conducted using an 
evaluable sample of 2876 participants enrolled in the Sequenced Treatment Alternatives to 
Relieve Depression (STAR*D) study.  Sociodemographic and clinical characteristics, and 
citalopram treatment characteristics were compared between participants with and without DM.  
Remission rates and time to remission were also compared between the two groups.  We found 
no difference in remission rates between participants with and without DM after adjustment for 
confounders.  Diabetics and non-diabetics received similar treatment, yet diabetics reported 
fewer side effects.  Depressed patients with and without DM appeared to remit at similar rates, 
indicating that a diagnosis of DM had no impact on MDD remission.  However, the lower 
prevalence of side effects reported by depressed participants with DM implies that they may be 
excellent candidates for more aggressive SSRI dosing. 
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 4.2 INTRODUCTION 
It has been previously observed that Major Depressive Disorder (MDD) often co-occurs with 
serious general medical comorbidities (GMCs).  The medical literature indicates that key 
sociodemographic and clinical characteristics, including GMCs, as well as other factors such as 
race and depression severity, can affect depression treatment response.1-3  Therefore, it is vital to 
determine how these comorbidities affect the treatment of depression in order to provide the 
most effective treatment to reach the overall goal: sustained remission. 
Diabetes Mellitus (DM) is often found comorbid with MDD.  In fact, patients with DM 
are 2-4 times more likely to be diagnosed with MDD.4, 5  In spite of this association, the existing 
literature on the impact of DM on depression treatment is limited.  Few studies have examined 
the impact of depression treatment in patients with DM in a controlled setting.6-9  The studies 
conducted have used either pharmacotherapy or psychotherapy, or both, with the overall 
endpoint being an improvement in glycemic control and a reduction in depression severity.  
Unfortunately, these studies were limited by small sample sizes, inconsistent results and the lack 
of a comparator group of depressed patients without diabetes. 
Given the established association of depression and DM,10 and the increasing prevalence 
of DM in the general population 11, there would be considerable clinical value in establishing the 
impact of DM on the outcomes of depression treatment.  A greater understanding of the effect of 
DM on depressed patients could provide clinicians with valuable information that could lead to 
adjustments in current depression treatment modalities to provide more effective treatment. 
The purpose of the current study was to systematically examine the effectiveness of 
antidepressant treatment in diabetic and non-diabetic depressed outpatients in a controlled 
clinical setting.  To our knowledge, this is the first study to do so. 
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 To maximize generalizability, such a study should focus on patients with depression who 
are receiving standard treatment in “real world” settings.  Therefore, our study focused on MDD 
treatment with the Selective Serotonin Reuptake Inhibitor (SSRI) citalopram, a commonly used 
pharmacotherapeutic treatment for non-psychotic MDD.  SSRIs comprise the “first line” of the 
available therapeutics for the treatment of MDD.  They are widely used as an alternative to the 
traditional Tricyclic antidepressants (TCAs) (e.g., imipramine) because they have a higher 
therapeutic index,12 less stringent dietary restrictions, they lack receptor antagonism,13, 14 and 
have fewer potentially fatal side effects in overdose (e.g., cardiac arrest).15   
SSRIs also facilitate the application of rigorous treatment in the effort to reach remission.  
Patients who do not reach full remission are prone to relapse, future treatment non-response, 
work impairment and adverse events.16-19  Therefore, clinicians should not settle for response 
when treating depressed patients, whether diabetic or not, but should aggressively push for full 
recovery through the use of optimal dosing or increased duration of antidepressant treatment.20  
SSRIs facilitate this as they do not require prolonged dose titration.21   
The current study was conducted as part of the Sequenced Treatment Alternatives to 
Relieve Depression (STAR*D) study, the largest study of a standardized course of antidepressant 
medication ever undertaken in the US.  STAR*D offered a unique opportunity to examine the 
effect of DM on the effectiveness of SSRI treatment for non-psychotic MDD in a “real world” 
setting (e.g., both primary and clinical care settings).  One of the unique features of STAR*D is 
that remission was defined a prior as the primary endpoint and treatment was considered to be a 
failure if participants failed to remit.22, 23   
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 This report addresses the following:  
1) Do remission and response rates to citalopram treatment of non-psychotic 
MDD differ in patients with and without DM? 
2) Do sociodemographic or clinical characteristics at baseline, treatment 
characteristics, serious adverse events, or side effects differ in patients with and 
without DM? 
4.3 METHODS 
Description of STAR*D 
The methodology of STAR*D has been described in greater detail elsewhere.22,23  Briefly, 
STAR*D was a multisite study to define prospectively which of several treatment options were 
most effective for outpatients diagnosed with non-psychotic, unipolar MDD who reported an 
unsatisfactory clinical outcome to an initial treatment of citalopram and, if necessary, subsequent 
pharmacotherapeutic and/or psychotherapeutic treatment(s).   
 
Study Participants 
STAR*D recruited patients 18-75 years of age who had a diagnosis of unipolar, non-psychotic 
MDD and were seeking routine care in either primary care (N=18) or psychiatric care (N=23) 
clinic settings across the US.  Advertisementing for participants was proscribed.  Patients met the 
diagnosis criteria for MDD if they scored ≥14 on the 17-item Hamilton Rating Scale for 
Depression (HRSD17),24,25 which was administered and scored by Clinical Research Coordinators 
(CRCs) at study entry.  CRCs confirmed the diagnosis of non-psychotic MDD using the 
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 checklist of DSM-IV criteria.  Patients were ineligible if they 1) were breast-feeding, pregnant or 
intending to conceive in the nine months subsequent to study entry; 2) had a principal diagnosis 
of eating disorder, obsessive compulsive disorder, bipolar or psychotic disorder; 3) had substance 
abuse or dependence requiring inpatient treatment; 4) had pre-existing GMCs contraindicating 
the STAR*D protocol antidepressants; or 5) had a medically documented history of intolerance 
or non-response (in the current major depressive episode) to any STAR*D protocol 
antidepressant used in the first two treatment steps. 
All risks, benefits, and adverse events associated with each STAR*D treatment was 
explained to study participants, who provided written informed consent prior to study 
participation.  Data were collected using HIPAA guidelines.  All study protocols and 
documentation were reviewed and approved by the Institutional Review Boards at the National 
Coordinating Center (University of Texas, Southwestern) and at each Regional Center and 
Clinical Site.  Participant safety and study data management processes were monitored by the 
Data Coordinating Center (Epidemiology Data Center, University of Pittsburgh) and the Data 
Safety Monitoring Board at the National Institute of Mental Health (NIMH).   
Eligible, consented participants were enrolled into the first level of STAR*D (Level 1) 
and received a 12-14 week course of treatment with up to six post-baseline clinic visits at weeks 
2, 4, 6, 9 and 12 (with a potential week 14 visit if needed).  In Level 1, all participants were 
treated with the SSRI citalopram. 
 
Diagnostic Measures 
CRCs administered measures of depression severity at baseline, including the HRSD17 and the 
16-item Quick Inventory of Depressive Symptomatology – Clinician-rated (QIDS-C16).  CRC's 
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 also gathered the 16-item QIDS-Self Report (QIDS-SR16).26, 27  The Research Outcome 
Assessors (ROAs) administered the 30-item Inventory of Depressive Symptomatology  
(IDS-C30)28, 29 and the HRSD17 by telephone interview within 24 hours of study entry and at 
Level 1 exit.  IDS-C30 items were used to estimate the prevalence of the atypical, melancholic 
and anxious depression subtypes.  The QIDS—both self report and clinician administered—were 
collected at baseline and at every clinic visit.   
At baseline, CRCs collected self-report sociodemographic data, as well as personal and 
familial medical histories.  Participants also completed the Psychiatric Diagnostic Screening 
Questionnaire (PDSQ)30, 31 at study entry.  The PDSQ was used to estimate the co-occurrence of 
the following 11 psychiatric disorders: bulimia, post-traumatic stress disorder, agoraphobia, 
generalized anxiety disorder, obsessive compulsive disorder, panic disorder, social phobia, 
alcohol abuse/dependence, drug abuse/dependence, hypochondriasis and somatoform disorder.  
CRCs collected GMC data at study entry using the 14-item Cumulative Illness Rating Scale 
(CIRS).32  The CIRS rates the severity of comorbidity relevant to each of the 14 organ systems 
using a 5 point scale (0-4; 0=No impairment, 4=Extremely severe/immediate treatment 
required).33, 34  For the purposes of this report, the CIRS summary score was calculated excluding 
the ratings for the CIRS Endocrine (which was used in the definition of DM) and Psychiatric 
Illness categories.   
Information on participant satisfaction, physical and mental functioning, and work 
productivity were collected via the telephone-based Interactive Voice Response (IVR) system at 
baseline, at week 6 and at Level 1 exit.  Participant satisfaction was assessed using the 16-item 
Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q),35 and mental and physical 
functioning were assessed using the 12-item Short Form Health Survey (SF-12).36  Work 
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 productivity was assessed using the 6-item Work and Social Adjustment Scale (WSAS)37 and the 
5-item Work, Productivity and Activity Impairment (WPAI)38 scale. 
 
The STAR*D Evaluable Sample 
Of the 4041 participants who enrolled in STAR*D, approximately two-thirds (n=2876) had 
evaluable outcomes.  This sample was constructed using the following criteria: 1) an 
independently confirmed score of ≥14 on the baseline ROA-collected HRSD17 and 2) the 
presence of post-baseline clinic visit data.  Of the 1165 participants excluded from the evaluable 
sample, 607 scored <14 on the baseline HRSD17, 324 were missing the independently confirmed 
baseline HRSD17 scores (ROA), and 234 failed to return for post-baseline clinic visits  
(Figure 4.1). 
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Screened 
N=4790 
Consented 
N=4117
Not offered consent 
or refused 
Enrolled 
N=4041
HRSD17 ≥14 
N=3110
Ineligible 
N=136 
HRSD17<14 
N=607
HRSD17 Missing 
N=324
Evaluable Sample
N=2876
Non-diabetics 
N=2641 
Diabetics 
N=235
Remission* 
N=741 
No remission** 
N=1900
Remission* 
N=49
No remission** 
N=186 
Failed to return 
N=234
 
 
*Remission: Score of ≤7 on the HRSD17 at Level 1 exit 
** No Remission: Score of >7 on the HRSD17 at Level 1 exit or missing the HRSD17 at Level 1 exit 
HRSD17: Hamilton Rating Scale for Depression, 17 item
 
Figure 4.1 STAR*D participant flow chart 
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 Diabetes Classification 
Participants were classified by diabetic status using the CIRS and the Medical Log (ML).  A 
participant was considered to have DM if one or both of the following criteria were met:  
 
1)  Diabetes had been reported on the CIRS 
2)  The participant reported use of oral hypoglycemic medication and/or insulin at 
baseline (recorded on the ML) 
 
No distinction was made between the types of DM.  A medical chart review was conducted 
at the STAR*D Bellefield Clinical Site (Bryan et al, unpublished) to evaluate the accuracy of 
participant self-report data (STAR*D research data) and medical evaluation data (medical 
chart review).  The measure of agreement between the STAR*D criteria data and the data 
from the chart abstraction was κ=0.76 (95% CI: 0.51-1.00).  This indicates very good 
agreement between the STAR*D criteria data and the chart abstraction.39 
 
Treatment Regimen 
The SSRI citalopram was used in Level 1 treatment because it has been demonstrated to be well 
tolerated in different populations and has a good safety profile.40  The STAR*D treatment 
regimen is described in detail elsewhere.41   
 
Side Effects and Serious Adverse Events 
The impact of side effects was rated using the Frequency, Intensity and Burden of Side Effects 
Rating (FIBSER)42 scale at baseline and at each clinic visit.  The FIBSER is composed of three 
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 7-point subscales (0 to 6) that measure the frequency, intensity and burden of side effects, 
respectively.   
Serious adverse events (SAEs) were monitored at all levels of the STAR*D organization.  
The Data Coordinating Center and the Medical Safety monitors at the National Coordinating 
Center worked in conjunction with the Regional Center Directors and the CRCs to ensure the 
proper resolution and documentation of all SAEs.  The Data Safety Monitoring Board at the 
NIMH monitored the resolution of all SAEs.   
  
 
Outcome Measures 
The primary outcome measure was the HRSD17, which was administered over the telephone in 
either English or Spanish by ROAs who were masked to the participant’s treatment level.  
Remission was defined a priori as a total HRSD17 score ≤7.  The secondary endpoint of 
remission was defined a priori as a total score ≤5 on the QIDS-SR16.  Response was defined as a 
reduction of ≥50% from the baseline QIDS-SR16.  Non-remitters were defined as participants 
with depression severity scores above the designated cutoff points on the HRSD17 and the QIDS-
SR16, or those who were missing their HRSD17 score at Level 1 exit. 
 
Statistical Analyses 
STAR*D Level 1 treatment data were used in the statistical analyses.  Descriptive statistics, 
including measures of central tendency and dispersion, were calculated for all continuous 
variables.  Frequency distributions were also determined for all categorical data.  Statistical 
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 differences in the discrete baseline characteristics between participants with and without DM 
were determined using the Chi-Square statistic and exact Fisher’s Test.  Statistical differences in 
the continuous baseline characteristics between participants with and without DM were 
determined using the Student’s t-test or the Wilcoxon test.  
Logistic regression models were used to determine the association of response and 
remission with diabetes status, as well as whether there was a differential association of DM with 
remission by race.  General linear models were generated to test the association of the final 
measure of depression severity (QIDS-SR16) with diabetes status.  The above logistic regression 
models and general linear models were also run with adjustment for baseline characteristics not 
balanced across Regional Center and participants with and without DM.  These models included 
the main effects for race and DM, and the two-way interaction terms adjusted for all relevant 
socio-demographic variables, clinical characteristics and the CIRS summary score.  All adjusted 
analyses were performed twice, once with and once without adjustment for the CIRS total score.  
This was done to address the multi-organ impact of a diagnosis of DM.  Survival analysis (i.e., 
Kaplan-Meier curves and the Log Rank Test) were also used to examine the differences in times 
to remission and response in participants with and without DM.  Statistical significance for all 
tests was set at p<0.05. 
4.4 RESULTS 
We found no differences in baseline socio-demographic and clinical characteristics between the 
patients included in the evaluable sample and those who had been excluded.  The data in      
Table 4.1 summarize baseline socio-demographic and clinical characteristics, depression 
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 severity, physical and mental functioning, and quality of life for participants in the evaluable 
sample with and without DM.  Participants with DM were more likely to be black, Hispanic, 
unemployed and single.  Participants with DM were more likely to be treated in primary care 
settings, have public medical insurance, and have a higher prevalence of anxious depression and 
atypical depression than participants without DM.  Participants with DM were older (by an 
average of approximately 10 years), less educated, reported more GMCs and a later mean age of 
onset of their first major depressive episode, and experienced a longer length of illness.  
Participants with DM also reported higher mental functioning and lower physical functioning 
than non-diabetic participants.  Depression severity at study entry did not differ significantly 
between participants with and without DM. 
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 Table 4.1 Baseline characteristics by diabetes status for the STAR*D evaluable sample 
Categorical Characteristic 
Diabetic 
N=235 
% 
Non-Diabetic 
N=2641 
% 
p-value 
Gender 
Male  
Female 
 
96 (41) 
139 (59) 
 
947 (36) 
1694 (64) 
<.1300 
Race 
White 
African-American 
Other* 
 
162 (69) 
63 (27) 
10 (4) 
 
2018 (76) 
443 (17) 
180 (95) 
0.0003 
Hispanic 
No  
Yes 
 
187 (80) 
48 (20) 
 
2316 (88) 
325 (12) 
0.0004 
Employment 
Employed 
Unemployed 
Retired 
 
88 (37) 
122 (52) 
25 (11) 
 
1525 (58) 
976 (37) 
136 (5) 
<.0001 
Marital Status 
Never married 
Married 
Divorced/Separated 
Widowed 
 
115 (49) 
40 (17) 
64 (27) 
16 (7) 
 
1084 (41) 
783 (30) 
698 (26) 
73 (3) 
<.0001 
Setting 
Primary 
Specialty 
 
131 (56) 
104 (44) 
 
960 (36) 
1681 (64) 
<.0001 
Insurance 
Private 
Public  
None 
 
109 (47) 
55 (24) 
65 (28) 
 
1316 (51) 
342 (13) 
903 (35) 
<.0001 
Family history of depression 
No 
Yes 
 
137 (58) 
98 (42) 
 
1131 (43) 
1487 (57) 
<.0001 
Family history of mood disorder 
No 
Yes 
 
131 (56) 
104 (44) 
 
1074 (41) 
1543 (59) 
<.0001 
Family history of suicide 
No 
Yes 
 
228 (97) 
7 (3) 
 
2514 (96) 
95 (4) 
0.6000 
Anxious depression 
No  
Yes 
 
85 (36) 
150 (64) 
 
1261 (48) 
1380 (52) 
0.0007 
Atypical depression 
No  
Yes 
 
179 (76) 
56 (24) 
 
2155 (82) 
485 (18) 
0.0400 
Melancholic Depression 
No  
Yes 
 
187 (80) 
48 (20) 
 
2013 (76) 
627 (24) 
0.2500 
Psychiatric comorbidities 
0 
1 
2 
3 
4+ 
 
79 (34) 
74 (32) 
31 (13) 
22 (9) 
29 (12) 
 
936 (35) 
686 (26) 
437 (17) 
239 (9) 
343 (13) 
0.3700 
*Other = Multiracial, Native American. Alaskan/Pacific Islander, Asian American 
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 Table 4.1 (continued) 
 
 
Continuous Characteristic 
Diabetic 
N=235 
Mean (SD) 
Non-Diabetic 
N-2641 
Mean (SD) 
p-value 
Age 50.4 (10.4) 39.9 (12.9) <.0001 
Years of education 12.4 (3.8) 13.5 (3.2) <.0040 
Household Income(Monthly USD) 1991 (2610) 2388 (3061) 0.0700 
    
General Medical Comorbidities    
CIRS Total Score 6.6 (3.7) 3.8 (3.3) <.0001 
    
Clinical Characteristics    
Age at first MDE 31.4 (16.5) 24.8 (14.0) <.0020 
Length of illness (months) 31.1 (65.5) 23.9 (50.3) 0.0050 
Number of MDEs 6.6 (12.4) 5.9 (11.3) 0.8300 
    
Depression severity at baseline    
Base HRSD17 Total Score 22.0 (5.2) 22.0 (5.2) 0.4600 
Base IDS-C30 Total Score 38.9 (10.3) 38.5 (9.5) 0.4900 
Base QIDS-C16 Total Score 16.9 (3.2) 16.77 (3.2) 0.9800 
Base QIDS-SR16 Total Score 16.2 (4.2) 16.2 (3.9) 0.9200 
    
Function and Quality of Life    
SF-12    
MCS-12 28.9 (9.0) 25.3 (8.0) <0.0001 
PCS-12 40.3 (11.4) 49.5 (11.8) <0.0001 
WSAS Total Score 25.4 (9.9) 24.9 (8.6) 0.1600 
Q-LES-Q Total Score 37.8 (15.6) 39.4 (14.2) 0.2100 
CIRS: Cumulative Illness Rating Scale 
MDE: Major Depressive Episode 
HRSD17: Hamiliton Rating Scale for Depression, 17 item  
IDS-C30: Inventory for Depressive Symptomatology, Clinician rated, 30 item 
QIDS-C16: Quick Inventory for Depressive Symptomatology, Clinician rated, 16 item 
QIDS-SR16: Quick Inventory for Depressive Symptomatology, Self rated, 16 item 
SF-12: Short Form Health Survey, 12 item 
MCS-12: Mental Health Component Score 
PCS-12: Physical Health Component Score 
WSAS: Work Satisfaction and Activities Scale Summary Score 
Q-LES-Q: Quality of Life, Enjoyment and Satisfaction Scale Summary Score 
 
 
Upon entry into Level 1, STAR*D participants with and without DM were seen for an 
average of 4.8±1.5 visits and 4.9±1.6 visits, respectively (p=0.2000) (Table 4.2).  Participants 
with DM spent fewer days in treatment than did participants without DM (69.9±29.3 vs. 
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 73.8±27.7; p=0.0500).  Participants did not differ in maximum citalopram dosage (44.3±6.3 vs. 
45.4 ±15.8) or in time to first treatment (17.5 ±1.05 vs. 16.2 ± 7.4). 
 
 
Table 4.2 Treatment characteristics by diabetes status 
 
Treatment Characteristics 
Diabetic 
N=235 
N (%) 
Non-Diabetic 
N=2641 
N (%) 
p-value 
Maximum dose of citalopram 
<20 mg 
≥20 mg and <40 mg 
≥40 mg and <50mg 
≥50mg 
 
2 (1) 
51 (22) 
72 (30) 
110 (47) 
 
21 (1) 
629 (24) 
839 (31) 
1152 (43) 
0.8000 
    
Dose of citalopram at exit 
<20 mg 
≥20 mg and <40 mg 
≥40 mg and <50mg 
≥50mg 
 
5 (2) 
52 (22) 
74 (32) 
104 (44) 
 
69 (3) 
664 (25) 
810 (31) 
1098 (41) 
0.7000 
    
Time in treatment 
<4 weeks 
≥4 to <8 weeks 
≥8 weeks 
 
18 (8) 
39 (17) 
178 (75) 
 
305 (12) 
446 (17) 
1890 (72) 
0.1800 
    
Treatment Characteristics Mean±(SD) Mean±(SD)  
Number of visits 4.8 (1.5) 4.9 (1.5) 0.2000 
    
Time in treatment 
Days to first treatment 
Days in treatment 
 
16.2 (7.4) 
69.9 (29.3) 
 
 
17.5 (10.5) 
73.8 (27.7) 
 
0.0600 
0.0500 
 
Dose of citalopram 
Maximum dose 
Dose at exit 
 
44.3 (16.3) 
43.1 (16.3) 
 
45.4 (15.8) 
44.4 (15.9) 
 
0.3200 
0.2200 
 
 
The data shown in Table 4.3 summarize the side effects and serious adverse events of 
participants with and without DM.  Participants with DM suffered significantly less frequently 
from side effects than those without DM (p=0.0050), and they also experienced less intense side 
effects, though not to a significant degree.  We found no difference in side effect burden 
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 experienced by participants with and without DM.  Approximately 11% of the reported side 
effects occurred in diabetic participants (p=0.0006).  Participants with DM also experienced 
fewer serious adverse events (p=0.0140) and fewer psychiatric serious adverse events (p<.0001) 
compared to those without DM. 
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 Table 4.3 Side effects, serious adverse events, and attrition by diabetes status 
 
 
Side Effects, Serious Adverse Events, 
Attrition 
Diabetic 
n=235 
 n (%) 
Non-Diabetic 
N=2641 
n (%) 
 
p-value 
Maximum SE frequency* 
None 
10%-25% of the time 
50%-75% of the time 
90%-100% of the time 
 
 
52 (22) 
67 (29) 
55 (24) 
58 (25) 
 
396 (15) 
741 (28) 
859 (33) 
633 (24) 
0.0050 
Maximum SE Intensity* 
None 
Trivial 
Moderate 
Severe 
  
49 (21) 
61 (26) 
83 (36) 
39 (17) 
 
 
393 (15) 
732 (28) 
1090 (41) 
414 (16) 
0.0600 
Maximum SE Burden* 
No impairment 
Minimal-mild impairment 
Moderate-marked impairment 
Severe impairment-unable to function 
 
 
56 (24) 
93 (40) 
61 (26) 
22 (9) 
 
527 (20) 
1081 (41) 
803 (31) 
218 (8) 
 
0.3300 
Serious Adverse Events 
Death, non suicide 
Medical illness (hospitalization) 
Medical illness (no hospitalization) 
Psychiatric Hosp (Substance Abuse) 
Psychiatric Hosp (Suicidal ideation) 
Psychiatric Hosp (Worsening MDD) 
Psychiatric Hosp (Other) 
Suicidal Ideation (no hospitalization 
 
26 (21) 
0  
23  
0  
2  
0  
0  
0  
1  
97 (79) 
3  
35  
4  
6  
36  
6  
2  
5  
0.0006 
Serious Adverse Events  
At least 1 SAE 
At least 1 psychiatric SAE 
 
 
21 (17) 
3 (2) 
 
89 (72) 
55 (45) 
 
0.0140 
<.0001 
Departure due to Intolerance 
 
16 (7) 231 (9) 0.3100 
Maximum frequency, intensity and burden of side effects (FIBSER) ratings listed are the 
highest ratings received during citalopram treatment. 
SE: Side Effect 
MDD: Major Depressive Disorder 
SAE: Serious Adverse Event 
 
 
The differences in treatment outcome (i.e., remission) by diabetes status are shown in 
Table 4.4.  Using the HRSD17 and QIDS-SR16, participants with DM were less likely to reach 
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remission than those without DM.  However, no statistically significant differences were found 
after adjustment for regional center, socio-demographic factors, selected clinical features of 
depression and the CIRS score.  Nor were statistically significant differences found when the 
adjustments were performed without the CIRS summary score.  There were also no statistically 
significant differences between participants with and without DM regarding remission or 
response rates using the QIDS-SR16 depression severity ratings after statistical adjustment for 
regional center, socio-demographic factors, selected clinical features of depression and the CIRS 
score  The lack of association of DM with remission was consistent across the racial groups 
(results not shown). 
Examination of the survival functions for time to remission (Figure 4.2) and time to 
response (Figure not shown) using the QIDS-SR16 showed no differences between participants 
with and without DM.  Inconclusive results were obtained from modeling remission (HRSD17 
and QIDS-SR16) with race and diabetes status. 
 Table 4.4 Differences in treatment outcome by diabetes status 
 
 
Adjusted with CIRS* Adjusted without CIRS**
Treatment Outcome 
Diabetic 
N=235 
n (%) 
Non-Diabetic 
N=2641 
n (%) 
OR Unadjusted p-value Adjusted* OR 
Adjusted*
p-value 
Adjusted**
OR 
Adjusted**
p-value 
 
HRSD17 Remission 
Yes  
No 
 
49 (20) 
186 (80) 
 
741 (28) 
1900 (72) 
 
0.680 0.0200 0.900 0.4400 
 
0.840 0.3100  
QIDS-SR16 Remission 
Yes  
No 
 
 
66 (28) 
169 (72) 
  
883 (33) 
1758 (67) 
0.829 0.230 0.990 0.9800 0.960 0.8100  
% Change in QIDS-SR16
<50% change 
>=50% change 
 
140 (60) 
95 (40) 
 
1393 (53) 
1248 (47) 
 
0.757 0.0450 1.010 0.9500 0.960 0.8000  
Adjusted with CIRS*               Adjusted without CIRS** Diabetic 
N=235 
Mean (SD) 
Non-Diabetic 
N=2641 
Mean (SD) 
Unadjusted 
p-value Diabetic LS Mean* 
Non-Diabetic 
LS Mean* 
Adjusted*
p-value 
Diabetic 
LS Mean** 
Non-Diabetic 
LS Mean** 
Adjusted** 
p-value 
          
QSTOT (at Level 1 exit) 
% Change in QIDS-SR16
9.8 (5.92) 
38.40 (33.85) 
9.08 (5.89) 
42.82 (35.13) 
0.0700 
0.0700 
9.20 
42.27 
9.11 
42.57 
0.8200 
0.9100 
9.09 
41.32 
9.41 
42.65 
0.4300 
0.5900 
* Adjusted using age, race, Hispanic ethnicity, CIRS total score (without endocrine and psychiatric illness categories), employment status, family history of 
depression, presence of anxious depression, atypical depression, age at first Major Depressive Episode, and length of illness.   
** Adjusted using age, race, Hispanic ethnicity, employment status, family history of depression, presence of anxious depression, atypical depression, age at first 
Major Depressive Episode, and length of illness, (adjusted CIRS score was not included). 
CIRS: Cumulative Illness Rating Scale 
HRSD17: 17-item Hamilton Rating Scale for Depression 
QIDS-SR16: 16-item Quick Inventory of Depressive Symptomatology – Self-Report 
LS: Least Square 
QSTOT: Quick Inventory of Depressive Symptomatology – Self-Report Summary Score at Level 1 Exit 
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Figure 4.2 Kaplan Meier curves and Log-Rank Test results 
 
 4.5 DISCUSSION 
Four previous controlled clinical studies have focused on the treatment of depression in diabetic 
patients.6-9  Lustman et al. (1997) conducted a placebo-controlled trial of 68 diabetic patients 
with poor glycemic control (28 with MDD) using nortryptiline as the antidepressant.6  Remission 
was achieved in 57% of the nortriptyline-treated patients compared to 35.7% of the placebo 
controlled, but the statistical comparisons were under-powered.  Nortriptyline also appeared to 
worsen glycemic control.  In contrast, Lustman et al. (2000) conducted a placebo-controlled 
study of fluoxetine in 60 diabetic patients that showed a positive trend toward remission and 
improved glycemic control.8  However, statistical comparisons may have been underpowered 
due to the small sample size.   
The two remaining controlled studies examined the efficacy of cognitive behavior 
therapy (CBT) in the treatment of depression in patients with diabetes.  In 1998, Lustman et al. 
showed that significantly more patients in the CBT group achieved remission than in the placebo 
group after controlling for the effects of “supportive attention” and “…enhanced diabetes control 
on mood”.7  They found no differences in glycemic control between the CBT group and the 
control group post treatment.  However, at 6 months post-treatment, the CBT group showed a 
significant improvement in glycemic control.  The limitations for this controlled study included 
the short treatment duration (8 weeks) and under-powered statistical comparisons (n=51 
diabetics).   
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 In the Pathways Study (n=329 diabetics), Katon et al, (2004)9 compared usual depression 
treatment against the use of an individualized depression treatment program that utilized the 
services of specially trained nurses who worked with the patients’ primary care providers.  
Intervention patients showed greater improvement in depression outcomes, but no change in 
glycemic control at the conclusion of one year of treatment.  The generalizability of this trial was 
limited as all patients were recruited from the same health care system, and potential treatment 
biases existed because patients from both treatment groups shared the same primary care 
practitioners.   
These four controlled studies have shown consistently that diabetics with MDD respond 
favorably to antidepressant treatment.  However, results were inconsistent regarding 
improvements in glycemic control across the studies.  Further, all four studies lacked a true 
comparator group (i.e., a non-diabetic, depressed control group) and each had limitations.   
In contrast, the current study is the first to compare treatment outcomes in depressed patients 
with and without diabetes.  The study’s large sample size, inclusion of patients from both 
psychiatric and primary care settings, and broad inclusion criteria contributed to the 
generalizability of the results. 
After adjustment for potential confounders, we found no difference in remission rates 
between diabetic and non-diabetic participants.  Participants with DM had fewer days to first 
treatment after baseline and were treated for overall fewer days with citalopram, but did not 
differ from non-diabetic participants regarding the number of clinic visits.  Participants with and 
without DM also did not differ significantly regarding citalopram dosing.  However, participants 
with DM reported fewer side effects than did non-diabetic participants.  This could indicate that 
depressed patients with DM might be better able to tolerate higher initial doses of SSRIs or a 
  85
 more rapid escalation to the optimal target dose.  This more aggressive dosing could potentially 
lead to a greater likelihood of these patients reaching remission, or reaching remission in a 
shorter treatment time.  
The limitations of this study include the lack of a placebo group and the lack of a medical 
diagnosis in the determination of diabetes status.  The criteria for the classification of DM were 
based on clinical assessment using participant self-report on the CIRS and on medical records 
indicating the use of oral hypoglycemics and/or insulin.  However, an additional diagnostic 
agreement study verified the accuracy of the DM classification through comparison with a 
medical chart review (Bryan et al, unpublished).   
Another concern was due to the multi-organ system impact of DM.  It is possible that in 
controlling for GMCs, we may have over-corrected by essentially adjusting for GMCs that are 
related to DM.  To address this, all multivariate analyses were performed twice, once with and 
once without the CIRS summary score.  In each multivariate analysis, we found essentially no 
difference between the CIRS and no-CIRS results. 
In conclusion, we found no significant difference in the remission rates of participants 
with and without DM after statistical adjustment for confounding factors.  Participants with DM 
received similar treatment regimens as participants without DM and reported fewer side effects.  
If the goal of depression treatment is sustained remission, this could imply that diabetic patients 
may be excellent candidates for more aggressive dosing with SSRIs.  Future controlled studies 
are needed to focus on a longer duration of treatment and on diabetic patient groups who are at 
an even greater risk. 
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 5.1 ABSTRACT 
Diabetes Mellitus (DM) is often comorbid with major depressive disorder, yet the impact and 
types of side effects experienced by diabetics receiving antidepressant treatment have not been 
examined.  The side effects of anti-depressant treatment are the primary reason for treatment 
non-compliance.  Over half of patients taking antidepressants are non-compliant with treatment, 
and this can result in premature discontinuation of, or lack of response to, antidepressant 
treatment.  This study examined antidepressant treatment side effects in depressed patients with 
and without DM to determine if side effects differed between groups.  Data on the frequency, 
intensity, burden and types of side effects experienced by depressed patients receiving 
antidepressant treatment with citalopram were analyzed as part of the Sequenced Treatment 
Alternatives to Relieve Depression study.  The maximum ratings of side effects reported during 
treatment, side effect ratings reported at the end of treatment, and specific side effects reported 
were compared between participants with and without DM.  Diabetic participants reported a 
lower impact of side effects (frequency, intensity and burden) from citalopram treatment than 
non-diabetics.  Diabetics reported experiencing more side effect symptoms, (e.g., blurry vision 
and tremors), but these were consistent with the diagnosis of DM.  These results were limited by 
a lack of available baseline side effect data for comparison.  Diabetic participants experienced 
fewer side effects than non-diabetics, and the types experienced differed between groups.  
Diabetic participants experienced side effects consistent with DM, as well as difficulties that 
could be either DM symptoms or side effects of citalopram treatment. 
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 5.2 INTRODUCTION 
Major Depressive Disorder (MDD) is a serious mental health problem that affects approximately 
16 million individuals in the US[1].  Current estimates show that the majority of these 
individuals receive little or no treatment[2].  MDD is associated with high morbidity and 
mortality[3], profound mental and physical impairment and losses in worker productivity, which 
can result in high indirect and direct societal costs[2].   
MDD often occurs concurrently with serious medical comorbidities, such as cancer and 
Diabetes Mellitus (DM).  Previous studies reported that individuals with DM are twice as likely 
to have MDD[4-6].  Unfortunately, MDD can be a risk factor for noncompliance with medical 
treatment[7].  Therefore, MDD must be treated appropriately when it occurs concurrently with 
DM to minimize the chances of patient non-compliance.    
Selective Serotonin Reuptake Inhibitors (SSRIs) are the most commonly prescribed 
antidepressants.  They have revolutionized the treatment of MDD with advantages that include a 
better safety profile, benign side effects, a reduction in the likelihood of fatal cardiac events, and 
ease of dose titration[8].  SSRIs are also better tolerated than the traditional Tricyclic 
antidepressants (TCAs) and have lower discontinuation rates[9, 10].  SSRIs have similar 
therapeutic effects when compared to TCAs; however, SSRIs have a longer drug-refractory 
period (4-6 weeks) before changes in depression severity are observed[11].  Examples of SSRIs 
include citalopram, sertraline and fluoxetine.   
Citalopram was first approved for use in the US in 1999[12].  The safety and efficacy of 
citalopram have been reported in a large number of controlled clinical trials over the past 10 
years[8].  These studies have shown that citalopram is a reliable, effective antidepressant that can 
be used safely in many patient populations (e.g., the elderly)[13].  It has also been shown to be 
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 effective in preventing the relapse and recurrence of MDD[14,15].  The most common side 
effects associated with citalopram treatment are sleep disturbances, gastrointestinal disturbances 
(e.g., nausea, vomiting), excessive sweating, headache, sexual dysfunction and tremors.   
Side effects are often part of the antidepressant treatment process.  They can have a 
detrimental impact on patient adherence to treatment and can cause increased attrition in 
controlled studies[16].  Further, clinicians need to understand and anticipate the impact of 
adverse events reported by depressed patients.  When treating depression, clinicians must engage 
in a delicate balancing act as they must not only anticipate and manage side effects, but must also 
determine the optimal dose of antidepressants required to effect sustained MDD remission.   
Given the prevalence of comorbid DM in patients with MDD, it would be useful to know 
whether side effects from citalopram treatment differ in depressed patients with and without DM.  
Such information would help clinicians to adapt existing treatment modalities to individual 
patient needs, and to better educate patients about what to expect during treatment, thus 
increasing the probability of patient adherence to the MDD treatment regimen.   
To date, only four controlled studies on the effect of antidepressant [17,18] and/or 
psychotherapeutic treatments[15,19] on depression in patients with DM have been conducted.  
These studies focused on the treatment of MDD in patients with diabetes and on improving 
glycemic control.  The frequency and type of side effects from antidepressant treatment were not 
discussed in these reports. 
The purpose of the current study was to determine whether side effects from citalopram 
treatment differ in depressed patients with and without DM.  It was conducted as part of the 
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study[20, 21], which was 
the largest antidepressant medication trial conducted in the US to date.  STAR*D offered a 
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 unique opportunity to examine the differences in side effects reported by patients with unipolar, 
non-psychotic MDD with and without DM who were undergoing antidepressant treatment with 
citalopram.  To our knowledge, this is the first study to examine the frequency, intensity, burden 
and type of side effects experienced by diabetic and non-diabetic depressed outpatients being 
treated for non-psychotic MDD in both primary and psychiatric care settings. 
5.3 METHODS 
Study Population 
Description of STAR*D 
Subjects in this report were identified on the basis of their participation in the STAR*D study.  
STAR*D was a multi-site, prospective, series of clinical trials designed to examine the 
effectiveness of various combinations of pharmacotherapeutic and/or psychotherapeutic 
treatment in outpatients with unipolar, non-psychotic depression at either primary or psychiatric 
care clinic settings.  The methodology of STAR*D has been described in greater detail 
elsewhere[20, 21].  Broadly, though, the goal of STAR*D was to define prospectively which of 
several treatment options were most effective for participants who had unipolar, non-psychotic 
MDD.   
STAR*D participants (N=4041) were outpatients who had been diagnosed with unipolar, 
non-psychotic MDD and were seeking care in 18 primary and 23 psychiatric care clinics across 
the US.  Eligible participants were between the ages of 18-75 years.  A diagnosis of MDD was 
confirmed a review of DSM-IV checklist criteria at study baseline and a score of >14 on the 
Hamiliton Rating Scale for Depression (17 item) (HRSD17) [22, 23] by the Clinical Research 
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 Coordinators (CRCs) at study entry.  Advertising for participants was not permitted.  Broad 
inclusion and minimal exclusion criteria were used to ensure recruitment of a representative 
sample.  Patients who were either 1) were breast-feeding, pregnant, or intending to conceive in 
the nine months subsequent to study entry or 2) had a principal diagnosis of eating disorder, 
obsessive-compulsive disorder, bipolar or psychotic depression or  3) had substance abuse or 
dependence requiring inpatient treatment; or 4) had pre-existing general medical conditions 
contraindicating the STAR*D protocol antidepressants or 5) had a medically documented history 
of non-response or intolerance (in the current major depressive episode) to any antidepressant 
used in the first two levels of the STAR*D protocol were not eligible to participate. 
All risks, benefits and adverse events associated with each STAR*D treatment were 
explained to study participants, who provided written informed consent prior to study entry.  
Data were collected using HIPAA guidelines.  All study protocols and documentation were 
reviewed and approved by the Institutional Review Boards at the National Coordinating Center 
(University of Texas, Southwestern) and at each Regional Center and Clinical Site.   
Participant safety and study data management processes were monitored by the Data 
Coordinating Center (Epidemiology Data Center, University of Pittsburgh) and the Data Safety 
Monitoring Board at the National Institute of Mental Health (NIMH).  An internal SAE reporting 
system was developed by the staff at the Data Coordinating Center and the National 
Coordinating Center in conjunction with the Medical Safety Officers, the Regional Center 
Directors and the CRCs.  The Data Safety Monitoring Board at the NIMH monitored the 
resolution of all SAEs. 
All eligible, consented participants (N=4041) were enrolled into the first level of 
antidepressant treatment (Level 1) and received a 12-14 week course of citalopram with medical 
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 review at up to 6 post-baseline clinic visits (weeks: 2, 4, 6, 9,12 and a potential week 14 visit).  
This report is based upon the experiences related to citalopram observed among the participants 
during this initial phase of the STAR*D trial.  An evaluable sample of the enrolled participants 
(N=2876) was used in the statistical analysis.  The development of this sample is described in 
detail elsewhere[24]. 
 
Assessment of Baseline Characteristics 
The CRCs collected sociodemographic, medical and psychiatric history data (both personal and 
familial) at study entry.  Data on prescribed non-study medications were collected at study entry 
using the non-STAR*D Medication Log (ML).  General medical comorbidity (GMC) data only 
at study entry using the 14-item Cumulative Illness Rating Scale (CIRS)[25, 26].  The severity of 
morbidity in the CIRS was assessed using a 5-point scale (0-4; 0=No impairment, 4=Extremely 
severe/immediate treatment required).  For the purposes of this report, the CIRS summary score 
was calculated excluding the ratings for the CIRS Endocrine (which was used in the definition of 
DM) and the Psychiatric Illness categories.   
An interactive, telephone voice response system (IVR) system was used to collect self-
report data on participant life enjoyment and satisfaction using the 16-item Quality of Life 
Enjoyment and Satisfaction Questionnaire (Q-LES-Q)[27], on physical and mental function 
using the 12-item Short Form Health Survey (SF-12)[28], and on work productivity using the 6-
item Work and Social Adjustment Scale (WSAS)[29] and the 5-item Work, Productivity and 
Activity Impairment (WPAI)[30] scale.  These data were collected at study entry, at week 6 and 
at the completion of Level 1.   
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 Diagnostic Measures 
The primary outcome measure of depression severity was the HRSD17, which was administered 
at baseline by the CRCs.  Independent, blinded Research Outcome Assessors (ROAs) 
administered the HRSD17, as well as the Inventory of Depressive Symptomatology (IDS-C30) 
[31, 32] by telephone interview within 72 hours of study entry.  The HRSD17 and the IDS-C30 
were also administered at the completion of Level 1 antidepressant treatment (within 12-14 
weeks post entry).  The 16-item Quick Inventory of Depressive Symptomatology – Clinician-
rated (QIDS-C16)[33, 34] was administered at study entry and at all successive clinic visits to 
measure treatment response and inform clinical decision-making.  Participants also completed 
the 16-item Quick Inventory of Depressive Symptomatology – Self-Rated  (QIDS-SR16)[34] at 
each clinic visit to measure outcomes.    
 
Diabetes Classification 
The diabetes status of the participants was classified on the basis of information available in the 
CIRS and medication logs.  An individual was considered to have DM if one or both of the 
following criteria were met:  
 
1)  Diabetes had been reported on the CIRS 
2)  The participant reported use of oral hypoglycemic medication and/or insulin at 
baseline (recorded on the ML). 
 
No distinction was made between the types of DM.  A medical chart review was conducted at 
one clinical site (Bryan et al, unpublished) to evaluate the accuracy of participant self-report data 
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 (STAR*D research data) and medical evaluation data (medical chart review).  The measure of 
agreement between the STAR*D criteria data and the data from the chart abstraction was κ=0.76 
(95% CI: 0.51-1.00).  This indicates very good agreement between the STAR*D criteria data and 
the chart abstraction [35]. 
 
Side Effects 
Side effects were documented in the STAR*D study on the basis of responses on the Frequency, 
Intensity and Burden of Side Effects Rating (FIBSER)[36].  Study participants completed this 
measure at each post-baseline clinic visit.  The FIBSER is composed of three 7-point subscales 
that measure the frequency, intensity and burden of side effects, respectively.  For the purposes 
of this report, the maximum reported ratings of side effects during treatment and the side effects 
level reported at the last clinic visit were used in the statistical analysis.   
The Patient Rated Inventory of Side Effects (PRISE)[21] was also completed by 
participants at each post baseline clinic visit.  This instrument was used to categorize common 
side effects by organ systems.  For the purposes of this report, the side effects reported by 
participants at the last clinic visit were used in the statistical analysis.   
 
Statistical Analysis 
Descriptive statistics including means and standard deviations were calculated for 
continuous variables, and percentages were calculated for categorical variables.  Statistical 
differences in the discrete baseline characteristics between participants with and without DM 
were determined using the Chi-Square statistic and the exact Fisher’s Test.  Statistical 
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 differences in the continuous baseline characteristics between participants with and without DM 
were determined using the Student’s t-test or the Wilcoxon test.    
The Wilcoxon Mann Whitney test was used to test the significance of the maximum 
frequency, intensity and burden of side effect ratings reported in Level 1 treatment and reported 
at the last clinic visit.  Survival analyses (i.e., Kaplan-Meier curves and the Log-Rank Test) were 
used to examine the differences between participants with and without DM regarding the time to 
the first occurrence of the following side effect features: frequency ≥50% of the time, intensity of 
at least moderate level, and burden of at least moderate impairment.  Statistical significance for 
all tests was set at p<.05. 
 
5.4 RESULTS 
The sociodemographic and clinical characteristics of the 2876 participants by diabetes status are 
shown in Table 5.1.  A total of 235 subjects were identified as having diabetes.  Significantly 
larger proportions of participants with DM were black (27% vs. 17%, p=0.0003), older 
(50.4±10.4 vs. 39.9±12.9, p<.0001), Hispanic (20% vs. 12%, p=0.0004), unemployed (52% vs. 
37%, p<.0001), never married (49% vs. 41%, p<.0001) and reported fewer years of education 
(12.4±3.8 vs. 13.5±3.2, p=0.0040) compared to participants without DM.  Participants with DM 
were also more likely to be treated in primary care settings (56% vs., 36%), were older at the 
onset of their first MDD episode, and reported a longer duration of the current MDD episode.   
Diabetic participants also reported a higher prevalence of atypical (24% to 18%, p=0.0400) and 
anxious depression (64% vs. 52%, p=0.0007). 
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 Table 5.1 Baseline characteristics of the STAR*D evaluable sample  
 
Characteristic 
Diabetic 
N=235 
n (%) 
Non-Diabetic 
N=2641 
n (%) 
p-value 
Gender 
Male  
Female 
 
96 (41) 
139 (59) 
 
947 (36) 
1694 (64) 
0.1300 
Race 
White 
African-American 
Other* 
 
162 (69) 
63 (27) 
10 (4) 
 
2018 (76) 
443 (17) 
180 (95) 
0.0003 
Hispanic 
No  
Yes 
 
187 (80) 
48 (20) 
 
2316 (88) 
325 (12) 
0.0004 
Employment 
Employed 
Unemployed 
Retired 
 
88 (37) 
122 (52) 
25 (11) 
 
1525 (58) 
976 (37) 
136 (5) 
<.0001 
Marital Status 
Never married 
Married 
Divorced/Separated 
Widowed 
 
115 (49) 
40 (17) 
64 (27) 
16 (7) 
 
1084 (41) 
783 (30) 
698 (26) 
73 (3) 
<.0001 
Setting 
Primary 
Specialty 
 
131 (56) 
104 (44) 
 
960 (36) 
1681 (64) 
<.0001 
Insurance 
Private 
Public  
None 
 
109 (47) 
55 (24) 
65 (28) 
 
1316 (51) 
342 (13) 
903 (35) 
<.0001 
Family history of depression 
No 
Yes 
 
137 (58) 
98 (42) 
 
1131 (43) 
1487 (57) 
<.0001 
Family history of mood disorder 
No 
Yes 
 
131 (56) 
104 (44) 
 
1074 (41) 
1543 (59) 
<.0001 
Family history of suicide 
No 
Yes 
 
228 (97) 
7 (3) 
 
2514 (96) 
95 (4) 
0.6000 
Anxious depression 
No  
Yes 
 
85 (36) 
150 (64) 
 
1261 (48) 
1380 (52) 
0.0007 
Atypical depression 
No  
Yes 
 
179 (76) 
56 (24) 
 
2155 (82) 
485 (18) 
0.0400 
Melancholic Depression 
No  
Yes 
 
187 (80) 
48 (20) 
 
2013 (76) 
627 (24) 
0.2500 
Psychiatric comorbidities 
0 
1 
2 
3 
4+ 
 
79 (34) 
74 (32) 
31 (13) 
22 (9) 
29 (12) 
 
936 (35) 
686 (26) 
437 (17) 
239 (9) 
343 (13) 
0.3700 
*Other= Multiracial, Native American. Alaskan/Pacific Islander, Asian American 
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 Table 5.1 (continued) 
 
Characteristic 
Diabetic 
N=235 
Mean (SD) 
Non Diabetic 
N-2641 
Mean (SD) 
p-value 
Age 50.4(10.4) 39.9 (12.9) <.0001 
Years of education 12.4 (3.8) 13.5 (3.2) <.0040 
Household Income(Monthly USD) 1991 (2610) 2388 (3061) 0.0700 
    
General Medical Comorbidities  
CIRS Total Score 
 
6.6 (3.7) 
 
3.8(3.3) 
 
<.0001 
    
Clinical Characteristics    
Age at first MDE 31.4 (16.5) 24.8 (14.0) <.0020 
Length of illness (months) 31.1 (65.5) 23.9 (50.3) 0.0050 
Number of MDEs 6.6 (12.4) 5.9 (11.3) 0.8300 
    
Depression severity at baseline    
HRSD17 Total Score 22.0 (5.2) 22.0 (5.2) 0.4600 
IDS-C30 Total Score 38.9 (10.3) 38.5 (9.5) 0.4900 
QIDS-C16 Total Score 16.9 (3.2) 16.8 (3.2) 0.9800 
QIDS-SR16 Total Score 16.2 (4.2) 16.2 (3.9) 0.9200 
    
Function and Quality of Life 
SF-12 
MCS-12 
PCS-12  
WSAS Total Score  
Q-LES-Q Total Score 
 
 
28.9 (9.0)  
40.3 (11.4)  
25.4 (9.9) 
37.8 (15.6) 
 
 
25.3 (8.0)  
49.5 (11.8) 
24.9 (8.63) 
9.4 (14.2)) 
 
 
<0.0001 
<0.0001 
0.1600 
0.2100 
    
CIRS: Cumulative Illness Rating Scale 
MDE: Major Depressive Episode 
HRSD17: 17-item Hamilton Rating Scale for Depression  
IDS-C30: 30-item Inventory for Depressive Symptomatology – Clinician-rated 
QIDS-C16: 16-item Quick Inventory for Depressive Symptomatology – Clinician-rated 
QIDS-SR16: 16-item Quick Inventory for Depressive Symptomatology – Self-rated 
SF-12: 12-item Short Form Health Survey 
MCS-12: Mental Health Component Score 
PCS-12: Physical Health Component Score 
WSAS: Work Satisfaction and Activities Scale Summary Score 
Q-LES-Q: Quality of Life, Enjoyment and Satisfaction Scale Summary Score 
 
 
The data in Table 5.2 show the maximum ratings reported by participants during 
citalopram treatment and the ratings from the last clinic visit with respect to the frequency, 
intensity and burden of side effects from citalopram treatment.  When the maximum ratings were 
reviewed for citalopram treatment, a statistically significant difference (p=0.0470) in the 
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distribution was noted with more diabetics having reported that they had not experienced any 
side effects to the non-diabetics (22% vs. 15%).  This pattern was again observed at the last 
clinic visit with over half of the diabetics reporting that they had not experienced any side effects 
(p<.0001).  Regarding intensity, more persons with DM reported that they had not experienced 
any side effects compared to non-diabetics in both the maximum ratings (21% vs. 15%, 
p=0.0030) and at the last clinic visit (53% vs. 42%, p<.0001).  Similar results were observed 
upon examination of the burden of side effects, with more persons with DM reported 
experiencing no impairment from side effects at both the maximum rating and the rating at the 
last clinic visit.  Overall, persons with DM reported lower scores than non-diabetics for the 
frequency, intensity and burden of side effects from citalopram treatment.
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Table 5.2 Frequency, intensity and burden of side effects reported by diabetes status in STAR*D patients during Level 1 treatment (maximum and at 
last clinic visit) using the FIBSER 
 
Maximum Last clinic visit in Level 1 Treatment
Side Effect Characteristic Diabetic N=235 
n (%) 
Non-Diabetic 
N=2641 
n (%) 
 
p-value 
Diabetic 
N=235 
n (%) 
Non-Diabetic 
N=2641 
n (%) 
 
p-value 
       
SE Frequency 
None 
10%-25% of the time 
50%-75% of the time 
90%-100% of the time 
 
 
52 (22) 
67 (29) 
55 (24) 
58 (25) 
 
396 (15) 
741 (28) 
859 (33) 
633 (24) 
0.0470  
124 (55) 
53 (21) 
26 (11) 
29 (13) 
 
1111 (42) 
783 (30) 
421 (16) 
314 (12) 
<.0001 
SE Intensity 
None 
Trivial 
Moderate 
Severe 
  
49 (21) 
61 (26) 
83 (36) 
39 (17) 
 
 
393 (15) 
732 (28) 
1090 (41) 
414 (16) 
0.0030  
124 (53) 
49 (21) 
33 (14) 
26 (11) 
 
1107 (42) 
747 (28) 
537 (20) 
238 (9) 
<.0001 
SE Burden 
No impairment 
Minimal-mild impairment 
Moderate-marked impairment 
Severe impairment-unable to 
function 
 
 
56 (24) 
93 (40) 
61 (26) 
22 (9) 
 
527 (20) 
1081 (41) 
803 (31) 
218 (8) 
<.0001  
135 (58) 
60 (26) 
26 (11) 
11 (5) 
 
1260 (48) 
842 (32) 
391 (15) 
136 (5) 
<.0001 
FIBSER: Frequency, Intensity and Burden of Side Effects Rating scale 
SE:Side Effect
 Figures 5.1, 5.2 and 5.3 show Kaplan-Meier curves for the proportion of STAR*D 
participants free from side effects that occurred ≥50% of the time, and for side effects of at least 
moderate intensity and of side effects of at least moderated impairment.  There were more 
diabetics free from side effects that occurred ≥50% of the time than non-diabetics (p=0.005).  
We found no statistically significant difference between the proportions of diabetics and non-
diabetics regarding side effects of at least moderate intensity and of side effects of at least 
moderated impairment.   
 
 
 
 
 
Figure 5.1 Proportion of STAR*D participants in the evaluable sample free of side effects 
occurring at least 50% of the time 
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Figure 5.2 Proportion of STAR*D participants in the evaluable sample free of side effects 
occurring with at least moderate intensity 
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Figure 5.3 Proportion of STAR*D participants in the evaluable sample free of side effects’ burden 
of at least modest impairment 
 
The types of side effects reported at the last clinic visit (grouped by organ system) are 
shown in Table 5.3.  Significantly larger proportions of diabetics than non-diabetics reported 
gastrointestinal disturbances (67% vs. 56%, p=0.0010), cardiovascular symptoms (40% vs. 30%, 
p=0.0030), dermatological symptoms (52% vs. 43%, p=0.0040), eye and ear problems (49% vs. 
30%, p<.0001), and genital/urinary symptoms (37% vs. 26%, p=0.0002).  A significantly smaller 
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 proportion of diabetics reported anxiety symptoms compared to non-diabetics (28% vs. 37%, 
p=0.0080).   
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 Table 5.3 STAR*D patients reporting the presence of side effects (categorized by organ systems) by diabetes 
status at the last clinic visit in Level 1 
 
Reported side effects (Presence) Diabetic 
N=235 
n (%) 
Non-Diabetec  
N=2641 
n (%) 
p value 
Gastrointestinal 
Diarrhea 
Constipation 
Dry mouth 
Nausea/Vomiting 
 
156 (67) 
52 (24) 
40 (19) 
74 (34) 
31 (14) 
1477 (56) 
458 (20) 
298 (13) 
787 (34) 
305 (13) 
0.001 
0.11 
0.02 
0.84 
0.58 
Heart 
Palpitations 
Dizziness 
Chest pain 
 
93 (40) 
22 (10) 
52 (24) 
32 (15) 
799 (30) 
213 (9) 
429 (18) 
206 (9) 
0.003 
0.59 
0.04 
0.004 
Skin 
Rash 
Increased perspiration 
Itching  
Dry skin 
 
122 (52) 
12 (6) 
40 (19) 
50 (23) 
58 (27) 
1122 (43) 
162 (7) 
395 (17) 
426 (18) 
531 (23) 
0.004 
0.45 
0.53 
0.07 
0.16 
Nervous System 
Headache 
Tremors 
Poor coordination 
Dizziness 
 
133 (57) 
84 (39) 
36 (17) 
26 (12) 
38 (18) 
1434 (55) 
928 (40) 
268 (11) 
249 (11) 
389 (17) 
0.45 
0.84 
0.02 
0.52 
0.71 
Eyes/Ears 
Blurred vision 
Ringing in the ears 
 
113 (49) 
71 (33) 
51 (24) 
795 (30) 
404 (17) 
400 (17) 
<.0001 
<.0001 
0.02 
Genital/Urinary 
Difficulty urinating 
Painful urination 
Frequent urination 
Menstruation irregularity 
 
87 (37) 
17 (8) 
4 (2) 
56 (26) 
13 (6) 
688 (26) 
89 (4) 
48 (2) 
443 (19) 
112 (5) 
0.0002 
0.004 
0.85 
0.01 
0.42 
Sleep 
Difficulty sleeping 
Sleeping too much 
 
127 (55) 
86 (40) 
39 (18) 
 
1511 (58) 
975 (42) 
430 (18) 
0.38 
0.61 
0.92 
Sexual Dysfunction 
Loss of sexual desire 
Trouble achieving orgasm 
Trouble with erections 
 
110 (47) 
70 (33) 
36 (17) 
32 (15) 
1113 (42) 
689 (30) 
469 (20) 
177 (8) 
0.15 
0.35 
0.24 
0.0002 
Other symptoms 
Anxiety 
Poor concentration 
General malaise 
Restlessness 
Fatigue 
Decreased energy  
162 (70) 
60 (28) 
63 (29) 
28 (13) 
57 (27) 
87 (40) 
84 (39) 
1916 (73) 
865 (37) 
749 (32) 
338 (14) 
692 (30) 
931 (40) 
852 (37) 
0.28 
0.008 
    0.40 
0.56 
0.33 
0.87 
0.46 
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 5.5 DISCUSSION 
This report indicates that overall, diabetic participants reported experiencing depression side 
effects at lower frequencies and intensities than non-diabetics.  Fewer persons with diabetes 
reported experiencing greater that moderate impairment from side effects.  Diabetic participants 
also reported experiencing side effects later than non-diabetics.  To our knowledge, this is the 
first study to examine side effects in diabetes and non-diabetic outpatients receiving treatment 
for MDD.   
These results may provide valuable information to clinicians to aid in the adjustment of 
antidepressant medication and also in the education of the patient.  Addressing the impact of side 
effects is an integral part of depression treatment.   
Clinicians have to carefully adapt treatments to minimize side effects and optimize 
antidepressant dosing in order to achieve sustained remission.  The increased tolerability and 
effectiveness of the newer SSRIs have greatly improved the chances of attaining and maintaining 
remission.  However, while harmful side effects are less common with SSRIs, benign and 
transient side effects are prevalent[16].  Side effects can hinder patient recovery and adversely 
affect patient treatment compliance[16, 37].   
Clinicians are encountering increasing numbers of patients with multiple serious medical 
and mental illnesses, particularly in the primary care setting.  In response to this, clinicians have 
had to develop more flexible disease management plans in order to meet the needs of an 
increasingly more complex patient population.  This includes educating the patient regarding the 
types of side effects to be expected during the course of treatment in an effort to improve patient 
compliance and reduce discontinuation rates.   
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 Four previous controlled studies have focused on the treatment of MDD in patients with 
DM [15, 17-19].  These four controlled studies have shown consistently that diabetics with MDD 
respond favorably to antidepressant treatment.  Further, all four studies lacked a true comparator 
group (i.e., a non-diabetic, depressed control group) and each had limitations.  None of these 
studies reported on the frequency, intensity burden, or types of side effects experienced by these 
patients.   
Several side effects were reported by persons with DM in this study which could be of 
some concern in a diabetic patient population.  The most common side effects associated with 
citalopram treatment are gastrointestinal and sleep disturbances, sexual dysfunction, excessive 
sweating, menstrual anomalies, anxiety and tremors.  While diabetic participants reported fewer 
side effects overall, they did report side effects related to gastrointesinal disturbance symptoms, 
tremors, erectile dysfunctions and anxiety more frequently than non-diabetics.  Persons with DM 
also reported more heart, eye and skin symptoms that non-diabetics.  It was difficult to determine 
if these reported symptoms were due to citalopram treatment alone or if they were present in 
higher frequency among persons with DM at the start of the study.  Also several of these 
symptoms, e.g. gastrointestinal disturbance symptoms are consistent with the health effects of 
DM.  However, since the FIBSER results indicate a lower frequency of side effects in diabetic 
participants, one can speculate that the diabetic participants presented with many of the side 
effects at study entry. 
STAR*D was the largest study of depression to be conducted in the US.  Its strengths 
included a large sample size (N=4041), broad inclusion criteria, and an outpatient sample 
recruited from both primary care and psychiatric care settings.  These features allow for a greater 
generalizability of the results.   
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 The limitations of this study include the lack of a clinical diagnosis of diabetes, the lack 
of side effects/symptom data at baseline and the lack of a placebo group.  The criteria for the 
classification of DM were based upon patient self-report on the CIRS and on the use of oral 
hypoglycemics and/or insulin (recorded on the ML).  However, an agreement study was 
conducted at a STAR*D clinical site (Bryan et al., unpublished) where the accuracy of the DM 
classification was verified through comparison with a medical chart review.  The lack of side 
effects/symptom data at baseline made it difficult to determine if there were any changes in the 
side effects before initiation of citalopram and those experienced at the conclusion of treatment.    
In summary, this study shows that fewer STAR*D participants with DM reported 
experiencing side effects of citalopram treatment than non-diabetics.  Participants with DM 
differed from those without DM in the types of side effects that they reported, many of which 
were consistent with the diagnosis of DM.  There was an overlap between the symptoms of DM 
and the side effects which can result from acute citalopram treatment in diabetic STAR*D 
participants, e.g., gastrointestinal disturbances and sexual dysfunction.  This may provide a 
possible avenue for the treating clinician to better educate patients about the negative synergistic 
effect of co-occurring MDD and DM and to work with patients to develop an individualized 
disease management plan to minimize the side effects from MDD treatment in DM.  This 
information may also aid clinicians in adapting existing treatment modalities to the needs of the 
patient and also to better educate patients about what to expect during treatment and thus 
increase the probability of patient adherence to the MDD treatment regimen.   
Future studies include examining the mediating effects of side effects on remission rates 
of diabetics and non-diabetics receiving treatment for MDD in successive treatment levels of 
STAR*D.  Inferences from comparisons will not be hindered by a lack of baseline data as side 
 113
 effect data from the conclusion of Level 1 citalopram treatment can be used in comparisons with 
side effect data from successive STAR*D treatment levels.   
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 6.0  DISCUSSION 
6.1 SUMMARY OF FINDINGS 
This dissertation investigated the association of Diabetes Mellitus with response to depression 
treatment.  The analyses were conducted in the STAR*D cohort81, 82.  This cohort was comprised 
of 4041 participants from both primary and psychiatric clinic settings across the US.   
The first paper showed that more participants with DM were African-American, endorsed 
Hispanic ethnicity, had fewer years of education, were older, unmarried and were either 
unemployed/retired when compared to the non-diabetics in the STAR*D study.  When the 
clinical characteristics were compared, diabetic participants did not differ in the severity of MDD 
at entry from non-diabetics on three separate measures of depression.  This was surprising, given 
what had been consistently reported in the medical literature.  There were also no statistically 
significant differences in the quality of life, enjoyment and satisfaction and work satisfaction 
between diabetics and non-diabetics.  Atypical depression appeared to be associated with DM.  
This association (which remained statistically significant after adjustment for potential 
confounding factors) was perhaps spurious due to the overlap of DM symptoms with those of 
atypical MDD.   
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 Diabetics reported higher mental functioning, but although this was statistically 
significant after adjustment, it was not clinically meaningful.  Diabetics consistently reported 
lower physical functioning across different measures.   
The second paper focused on treatment outcomes at the conclusion of Level 1 treatment 
in STAR*D with the SSRI citalopram.  Using an evaluable sample of 2876 participants 83, socio-
demographic and clinical characteristics were compared between diabetics and non-diabetics.  
Diabetics in the evaluable sample were similar to what has been observed previously in the 
cohort of 4041.  One exception was the higher prevalence of anxious depression reported by 
diabetic patients.  Depression severity across three measures was again not statistically 
significant between diabetics and non-diabetic patients.  Mental functioning was higher in 
diabetic patients and physical functioning was statistically lower in diabetic patients.   
Diabetics had similar treatment characteristics e.g. mean duration of stay, maximum dose 
of citalopram, when compared to non-diabetics.  Diabetics reported fewer side effects than non-
diabetics, however, they experienced statistically more serious adverse events requiring 
hospitalization for medical comorbidities.  In contrast, non-diabetics experienced more serious 
adverse events resulting in hospitalization for suicidal ideation and worsening MDD.  Despite the 
similarity in the remission rates for diabetics and non-diabetics, diabetics rated the frequency and 
intensity of side effects at lower rates than non-diabetics implying that diabetics may be excellent 
candidates for more aggressive SSRI dosing. 
The third paper focused on the differences in the frequency, intensity, burden and types 
of side effects reported by diabetics at the completion of Level 1 treatment with citalopram.  
Diabetic patients reported lower maximum ratings for the frequency, intensity and burden of side 
effects.  They also reported lower ratings at the completion of Level 1.  Diabetics were 
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 significantly slower to report side effects occurring at least 50% of the time compared to non-
diabetics.  There was also no difference in the time to report side effect burdens of at least 
moderate impairment.  Diabetics reported significantly more types of side effects, but these were 
consistent with the diagnosis of DM.   
 
6.2 STRENGTHS 
The main strength of this study lies in the design of STAR*D81, 82.  STAR*D was a unique 
hybrid design incorporating elements of “effectiveness” and “efficacy” trials.  STAR*D differed 
from the traditional efficacy trial on the following ways: 1) broad inclusion criteria, 2) 
comparisons of active treatments, 3) focused on practical outcomes, e.g. functioning and 4) use 
of the primary care settings to recruit patients.  Traditional efficacy trials have very stringent 
inclusion and exclusion criteria and their findings are limited by the select participant sample.  
The results from STAR*D are more generalizable to the usual outpatient populations than what 
have been previously found in traditional clinical trials due to the nature of the design.   
STAR*D patients were not recruited through advertisements, but were recruited while 
receiving usual care in community settings.  The broad inclusion criteria and recruitment 
strategies resulted in a broader and more “real world” cohort of patients enrolled in STAR*D.  
The use of both primary and psychiatry care community clinics for recruitment added to the 
generalizability of the findings by reducing the selection bias that could result from only using 
participants from psychiatry clinics in university/private settings.  The large sample size 
provided ample power to the statistical comparisons and the MDD treatment protocol was such 
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 that it allowed the individualized management of antidepressant dosing within a pre-planned 
schedule.  This has strengthened the generalizability of the results.   
Clinicians now need more practical information on how to adapt disease management 
plans to provide individualized care to an increasingly more medically complex patient 
population.  The results from STAR*D and from this study can provide some of this information.   
 
6.3 LIMITATIONS 
STAR*D was primarily a study of MDD, not of DM.  The main limitation to this study is the 
lack of a clinical diagnosis of DM.  DM classification in this study was completed using patient 
self-report and by a review of patient medications.  The rate of DM may have been under-
reported as patients who chose not to report the diagnosis of DM and those who were 
undiagnosed would not have been ascertained by this self-report method.  However, the lack of a 
clinical diagnosis of DM was addressed through an independent review of a sub-sample of 
participant, medical chart data.  The STAR*D criteria for DM status identified 3 more 
participants with DM than a review of participant medical charts.  The measure of agreement 
between the STAR*D criteria and the independent chart assessment was κ=0.76.   
Another key limitation was the lack of a measure of glycemic control.  MDD has an 
adverse effect on DM management, i.e. glycemic control and could potentially be used as a 
secondary outcome to measure improvements in depression severity.  Glycemic control is a ‘key 
indicator’ in DM disease management.84 
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 The effect of MDD treatment on the changes in the prevalence types of side effects could 
not be determined as there were no available baseline measurements of side effects.  This limited 
the applicability of the side effects’ data from the last clinic visit.   
 
6.4 CONCLUSION 
The results from the examination of the association of DM with response to depression treatment 
showed that DM is not independently associated with response to MDD treatment.  Diabetic 
depressed patients remitted at similar rates to non-diabetic depressed patients, but reported fewer 
side effects.  The mean duration of treatment was similar for both groups of patients, but overall 
it was longer than what has been currently observed in clinical practice.  The remission rates 
were 28% and 33% respectively for diabetic and non-diabetic patients.  This is lower that what 
has been previously observed in efficacy trials and shows that for at least 72% of the patients 
(diabetics), an SSRI or perhaps only one SSRI, is not an appropriate treatment for both diabetic 
depressed and non-diabetic depressed individuals.  Diabetics consistently endorsed more 
“physical” types of depressive symptomatology.  This may provide a possible focus for cognitive 
behavioral therapy (CBT) which has been shown to have some modest effects on glycemic 
control.76   
It is important to examine alternative modalities in the treatment of MDD, especially with 
there is comorbid DM.  This is of some clinical significance as the impact of poorly treated 
MDD on DM disease is profound.   
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 6.5 FUTURE STUDIES 
The importance of achieving and sustaining remission cannot be overstated.  Recent evidence in 
the medical literature has shown that patients who do not achieve full remission are prone to 
relapse, future treatment non-response, work impairment and adverse events, i.e., suicide.  Given 
the low remission rate achieved with citalopram treatment, the examination of the response to 
different combinations of pharmacotherapies (with and without psychotherapy) in diabetic and 
non-diabetic patients will be useful to treating clinicians.  Utilizing data from successive 
STAR*D treatment levels the following studies will be proposed:  
 
1) The examination of the types of residual depression symptoms in remitted diabetic and 
non-diabetic patients 
2) Differences in relapse rates of remitted and non-remitted patients by diabetes status 
3) The effect of different combinations of pharmacotherapeutic treatments on remission for 
diabetics and non-diabetic patients who did not remit with citalopram.   
 
6.6 CLINICAL SIGNIFICANCE 
These findings are of some importance to the clinician.  The lack of association of DM with 
MDD treatment response implies that clinicians can treat patients with DM similarly to those 
without DM for MDD.  However, there were key differences in the depressive symptomatology 
and types of side effects that were reported by diabetics when compared to diabetics.  This is of 
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 some importance as approximately 72% of diabetic patients did not achieve remission using 
traditional SSRI treatments.  The role of combination pharmacotherapy and psychotherapy in the 
treatment of MDD in patients with DM should be explored.   
 
6.7 PUBLIC HEALTH SIGNIFICANCE 
Untreated MDD adversely affects DM disease management and has been associated with the 
development of diabetes-related complications.  Untreated or poorly treated MDD in patients 
with DM has been reported to result  in higher utilization rates of health care services.85  The 
importance of developing MDD treatment modalities that result in sustained remission for 
individuals with MDD and DM cannot be over-stated. 
 125
  
6.8 LITERATURE CITED 
1. The invisible disease: depression. National Institue of Mental Health, 2001. (Accessed 
Dec 1st, 2006, at http://www.nimh.nih.gov/publicat/invisible.cfm.) 
2. National Diabetes Statistics fact sheet: general information and national estimates on 
diabetes in the United States. Bethesda, MD: U.S. Department of Health and Human 
Services, National Institute of Health 2005. (Accessed 12/1/2006, at 
http://diabetes.niddk.nih.gov/dm/pubs/statistics/references.htm.) 
3. Kessler RC, Berglund P, Demler O, et al. The Epidemiology of Major Depressive 
Disorder: Results from the National Comorbidity Survey Replication (NCS-R). Journal 
of the American Medical Association 2003;289(23):3095-105. 
4. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence if DSM-
III-R psychiatric disorders in the United Sates: Results for the National Cormorbidity 
Survey. Archives of General Psychiatry 1994;51(1):8-19. 
5. Insel T, Charney D. Research on major depression: strategies and priorities. Journal of 
the American Medical Association 2003;289:3167-8. 
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental 
Disorders. Fourth Edition, Text Revision ed. Washington, D.C.: American Psychiatric 
Association; 2000. 
7. Weissman MM, Bruce ML, Leaf PJ, Florio LP. Affective disorders. In: Robins LN, 
Regier DA, eds. Psychiatric disorders in America: the Epidemiologic Catchment Area 
Study. New York, NY: The Free Press; 1991:53-80. 
8. Robins L, Helzer J, Croughan J, Ratcliff K. National Institute of Mental Health 
Diagnostic Interview Schedule. Archives of General Psychiatry 1981;38:381-9. 
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental 
Disorders. Third Edition, Text Revision ed. Washington, D.C.: American Psychiatric 
Association; 1980. 
 126
 10. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of 
major depression in a national community sample: The National Cormorbidity Survey. 
American Journal of Psychiatry 1994;157(7):979-86. 
11. Robins L, Wing J, Wittchen H-U, et al. The Composite International Diagnostic 
Interview: An epidemological instrument suitable for use in conjunction with different 
diagnostic systems and in different cultures. Archives of General Psychiatry 
1989;45:1069-77. 
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental 
Disorders. Third Edition, Revised ed. Washington, D.C.: American Psychiatric 
Association; 1987. 
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental 
Disorders. Fourth Edition ed. Washington, D.C.: American Psychiatric Association; 
1994. 
14. Mark O, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in 
outpatient treatment of depression. Journal of the American Medical Association 
2002;287(2):203-9. 
15. Kessler RC, Berglund P, Chiu WT, et al. The US National Comorbidity Survey 
Replication (NCS-R): design and field procedures. International Journal of Methods in 
Psychiatric Research 2004;13(2):69-92. 
16. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime 
prevalence and age-of-onset distributions of DSM-IV disorders in the National 
Comorbidity Survey Replication. Archives of General Psychiatry 2005;62:593-602. 
17. Kessler R, Chiu WT, Delmer O, Walters EE. Prevalence, severity, and comorbidity of 
12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives 
of General Psychiatry 2005;62(617-627). 
18. Lepine J-P, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first 
pan-European study DEPRES (Depression Research in the European Society). 
International Clinical Psychopharmacology 1997;12:19-29. 
19. Pinkus H, Pettit A. The societal costs of chronic major depression. Journal of Clinical 
Psychiatry 2001;61(Suppl 6):5-9. 
 127
 20. Hayden E, Klein D. Outcome of dysthymic disorder at 5-year follow-up: The effect of 
familial psychopathology, early adversity, personality, comorbidity, and chronic stress. 
American Journal of Psychiatry 2001;158(11):1864-70. 
21. Blumenthal S. Women and depression. Journal of Women's Health 1994;3:467-79. 
22. Lieb R, Isenee B, Hofler M, Pfister H, Wittchen H. Parental major depression and the risk 
of depression and other mental disorders in offspring: A prospective-longitudinal 
community study. Archives of General Psychiatry 2002;59(4):365-74. 
23. Kessler RC, McGonagle KA, Swartzc M, Blazer DG, Nelson CB. Sex and depression in 
the National Comorbidity Survey I: Lifetime prevalence, chronicity and recurrence. 
Journal of Affective Disorders 1993;29(2-3):85-96. 
24. U.S. Department of Health and Human Services. Mental Health: A report of the Surgeon 
General. Rockville, MD: U.S. DHHS, Substance Abuse and Mental Health Services 
Administration, Center for Mental Health Services, NIH, NIMH; 1999. 
25. Frank E, Kupfer D, Parel J, et al. Three year outcomes for maintenance therapies in 
recurrent depression. Archives of General Psychiatry 1990;47(12):1093-9. 
26. Zajecka JM. Clinical issues in long-term treatment with antidepressants. Journal of 
Clinical Psychiatry 2000;61(Suppl 2):20-5. 
27. Cassano P, M F. Tolerability issues during long-term treatment with antidepressants. 
Annals of Clinical Psychiatry 2004;16:15-25. 
28. Lin EH, Simon G, Katon WK, et al. Can enhanced acute-phase treatment of depression 
improve long-term outcomes? A report of randomized trials in primary care. . American 
Journal of Psychiatry 1999;156(4):643-5. 
29. Schechter LE, Ring RH, Beyer CE, et al. Innovative approaches for the development of 
antidepressant drugs: Current and future strategies. NeuroRx 2005;2(4):590-611. 
30. Hiemke C, Hartter S. Pharmakinetics of selective serotonin reuptake inhibitors. 
Pharmacology and Therapeutics 1999;85:11-28. 
31. Keller MB. Citalopram therapy for depression: A review of 10 years of European 
experience and data from US clinical trials. Journal of Clinical Psychiatry 
2000;61(12):896-908. 
 128
 32. Benkert P, Grunder G, Wetsel H. Is there and advantage to venlafaxine in comparison 
with other antidepressants? Human psychopharmacology: clinical and experimental 
1997;12(53-67). 
33. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-
XR after failure of SSRIs for depression. N Engl J Med 2006;354(12):1231-42. 
34. Khawam EA, Laurencic G, Malone DA. Side effects of antidepressants: An overview. 
Cleveland Clinic Journal of Medicine 2006;73(4):351-61. 
35. Cassano P, Fava M. Depression and public health: An overview. Journal of Psychomatic 
Research 2002;53:849-57. 
36. Frasure-Smith N, Lesperance F, Gravel G, Masson A, Juneau M, Talajic M. Social 
support, depression and mortality during the first year after myocardial infarction. 
Circulation 2000;101(1919-1924). 
37. Lesperance F, Frasure-Smith N, Gravel G, Masson A, Juneau M. Major depression 
before and after myocardial infarction: Its nature and consequences.  . Psychosomatic 
Medicine 1996;58(99-110). 
38. Wells K, Golding J, Burnam M. Affective, substance use, and anxiety disorders in 
persons with arthritis, diabetes, heart disease, high blood pressure, or chronic lung 
conditions. General Hospital Psychiatry 1989;11:320-7. 
39. Gavard JA, Lustman P, Clouse RE. Prevalence of depression in adults with diabetes: An 
epidemiologic evaluation. Diabetes Care 1993;16:1167-78. 
40. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid 
depression in adults with diabetes--a meta-analysis. Diabetes Care 2001;24:1069-78. 
41. Wells KB, Golding J, Burnam M. Psychiatric disorder in a sample of the general 
population with and without chronic medical conditions. American Journal of Psychiatry 
1988;145:976-81. 
42. Lustman P, Anderson R, Freedland KE, de Groot M, M CR, E CR. Depression and poor 
glycemic control: A meta-analytic review of the literature. Diabetes Care 
2000;23(7):934-42. 
43. American Diabetic Association. Diagnosis and Classification of Diabetes Mellitus. 
Diabetes Care 2006;29(Supp1):S43-8. 
 129
 44. Atkinson M, Maclaren N. The pathogenesis of insulin dependent diabetes. New England 
Journal of Medicine 1994;331:1428-36. 
45. Ekoe J-M, Zimmet P, Williams R, eds. The Epidemiology of Diabetes Mellitus--An 
International Perspective. West Sussex, England; 2001. 
46. Davies J, Kawaguchu Y, Bennet S, et al. A genome wide search for human Type 1 
diabetes suceptibility genes. Nature 1994;371:130-6. 
47. Todd J, Bain S. A practical approach to identification of suceptibility genes for IDDM. 
Diabetes 1992;41:1029-34. 
48. Barnett A, Eff C, Leslie R, Pyke D. Diabetes in identical twins. Diabetologica 
1981;20:87-93. 
49. Thomson G, Robinson W, Kuhner M, Joe S, MacDonald M. Genetic heterogeneity, 
modes of inheritance, and risk estimates; a joint study of Caucasians with insulin-
dependent diabetes mellitus. American Journal of Human Genetics 1988;43:799-816. 
50. Warram J, Krolewski A, Gottlieb M, Kahn C. Difference in risk of insulin-dependent 
diabetes in offspring of diabetic mothers and diabetic fathers. New England Journal of 
Medicine 1984;311:149-52. 
51. Karnoven M, Tuomilehto J, Libman I, LaPorte R. Review of the recent epidemiological 
data on the worldwide incidence of Type 1 (insulin-dependent) Diabetes Mellitus. 
Diabetologica 1993;36(10):883-92. 
52. Reaven G. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607. 
53. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990-1998. 
Diabetes Care 2000;23(2):197-201. 
54. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing 
epidemics of obesity and diabetes in the United States. Journal of the American Medical 
Association 2001;286:195-200. 
55. Brancati FL, Whelton PK, Kuller LH, Klag MJ. Diabetes mellitus, race and 
socioeconomic status: A population-based study. Annals of Epidemiology 1994;6(1):67-
73. 
56. Connolly V, Unwin N, Sherriff P, Bilous R, Kelly W. Diabetes prevalence and 
socioeconomic status: a population based study showing increased prevalence of Type 2 
 130
 Diabetes Mellitus in deprived areas. Journal of Epidemiology and Community Health 
2002;54:173-7. 
57. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national 
schizophrenia sample. Schizophrenia Bulletin 2000;26:903-12. 
58. Mukherjee S. Family history if Type 2 diabetes in schizophrenia patients [letter]. Lancet 
1989;1:495. 
59. Regenold WT, Thapar RK, Marano C, S G, V KP. Increased prevalence of Type 2 
Ddiabetes Mellitus among psychiatric inpatients with bipolar I affect and schizoaffective 
disorders independent of psychotropic drug use. Journal of Affective Disorders 
2002;70:19-26. 
60. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with 
schizophrenia. Psychological Medicine 1999;29(3):697-701. 
61. Ryan M, Collins P, Thakore J. Impaired fasting glucose tolerance in first-episode, drug 
naive patients with schizophrenia. American Journal of Psychiatry 2003;160(2):284-9. 
62. Peyrot M, Rubin RR. Levels and risks of depression and anxiety symptomatology among 
diabetic adults. Diabetes Care 1997;20:585-90. 
63. Katon WK, Sullivan MD. Depression and chronic medical illness. Journal of Clinical 
Psychiatry 1990;51:3-11. 
64. De Groot M, Anderson R, Freedland KE, E CR, Lustman PJ. Association of depression 
and diabetes complications: a meta-analysis. Psychosomatic Medicine 2001;64(619-630). 
65. Barth J, Schumacher M, Hermann-Lingen C. Depression is a risk factor for mortality in 
patients with coronary heart disease: a meta-analysis. Psychosomatic Medicine 
2004;66(6):802-3. 
66. Jones DJ, Beach SRH, Forehand R, The Family Health Project Research Group. Disease 
status in African-American single mothers with HIV: the role of depressive symptoms. 
Health Psychology 2001;20(6):417-23. 
67. Goether J, Maljanian R, Wolf S, Hernandez P, Cabrera Y. The impact of depressive 
symptoms on the functional status of inner-city patients with asthma. Annals of Allergy 
Asthma and Immunology 2001;87(3):205-10. 
 131
 68. Armenian H, Pratt L, Gallo J, Eaton W. Psychopathology as a predictor of disability: a 
population-based follow-up in Baltimore, Maryland. American Journal of Epidemiology 
1998;148(3):269-75. 
69. Black SA, Markides KS. Depressive symptoms and mortality in older Mexican 
Americans. Annals of Epidemiology 1999;9:45-52. 
70. Fisher L, Chesla CA, Skaff MM, et al. Contributors to depression in Latino and European 
American patients with Type 2 diabetes. Diabetes Care 2001;24(10):1751-7. 
71. Fisher L, Chesla CA, Skaff MM, et al. The family and disease management in Hispanic 
and European-American patients with Type 2 diabetes. Diabetes Care 2000;23(3):267-72. 
72. Talbot F, Nouwen A. A review of the relationship between depression and diabetes in 
adults: Is there a link? Diabetes Care 2000;23(10):1556-62. 
73. Peyrot M, Rubin R. Persistence of depressive symptoms in diabetic adults. Diabetes Care 
1999;22(3):448-52. 
74. Black SA, Markides KS, Ray LA. Depression predicts increased incidence of adverse 
health outcomes in older Mexican Americans with Type 2 diabetes. Diabetes Care 
2003;26(10):2822-8. 
75. Rubin R, Peyrot M. Psychological issues and treatments for people with diabetes. Journal 
of Clinical Psychology 2001;57:457-78. 
76. Lustman P, Griffith LS, Freedland KE, Kissel SS, Clouse RE. Cognitive behavior therapy 
for depression in Type 2 Diabetes Mellitus: A randomized controlled trial. Annals of 
Internal Medicine 1998;129(8):613-21. 
77. Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and 
glycemic control in diabetes: results of a double-blind, placebo-controlled trial. 
Psychosomatic Medicine 1997;59(3):241-50. 
78. Lustman P, Freedland KE, Griffith LS, RE C. Fluoxetine for depression in diabetes: a 
randomized double-blind placebo-controlled trial. Diabetes Care 2000;23(5):618-23. 
79. Katon WJ, von Korff M, Lin EHB, et al. The Pathways Study: A randomized trial of 
collaborative care in patients with diabetes and depression. Archives of General 
Psychiatry 2004;61:1042-9. 
 132
 80. Petersen T, Iosifescu DV, Papakostas GI, Shear DL, Fava M. Clinical characteristics of 
depressed patients with comorbid Diabetes Mellitus. International Clinical 
Psychopharmacology 2006;21(1):43-7. 
81. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the sequenced 
treatment alernatives to relieve depression (STAR*D) study. Psychiatric Clinics of North 
America 2003;26(2):457-94. 
82. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve 
depression (STAR*D): Rationale and design. Controlled Clinical Trials 2004;25(1):119-
42. 
83. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for 
depression using measurement-based care in STAR*D: Implications for clinical practice. 
American Journal of Psychiatry 2006;163(1):28-40. 
84. De Groot M, Jacobsen AM, Samson JA, Welch G. Glycemic control and major 
depression in patients with Type 1 and Type 2 Diabetes Mellitus. Journal of 
Psychosomatic Research 1999;46(5):425-35. 
85. Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased 
health care use and expenditures in individuals with diabetes. Diabetes Care 
2002;25(3):464-70. 
 
 
 133
 APPENDIX A  RESULTS FROM THE AGREEMENT STUDY 
 
 
STAR*D Research Data Medical Chart Review  
 DM+ DM-  
DM+ 5 3 8 
DM- 0 170 170 
 5 173 178 
 
Sensitivity1= 100% Positive Predictive Value3= 62.5% 
Specificity2= 98.3% Negative Predictive Value4= 100% 
 False Positive Rate5 = <2% 
 
DM+ = Presence of Diabetes Mellitus 
DM- = Absence of Diabetes Mellitus 
1Sensitivity = Probability that a diseased individual will have a positive test result 
2Specificity = Probability that a disease-free individual will have a negative test result 
3Positive Predictive Value = Probability that an individual with a positive test result has the 
disease  
4Negative Predictive Value = Probability that an individual with a negative test result does not 
have the disease 
5False Positive Rate = Probability that a disease-free individual will have a positive test result 
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